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In 1944 the Swedish physician Jan Gösta Waldenström (1906-1996) reported two 
patients, displaying symptoms of oronasal bleeding, lymphadenopathy, anemia, 
thrombocytopenia, increased erythrocyte sedimentation rate (ESR) and an abnormal 
serum protein of high molecular weight.1,2 The absence of bone pain, lack of lytic 
bone lesions on radiographs and the presence of an excess of lymphoid cells in bone 
marrow, made him understand that this disease entity was different from multiple 
myeloma, in which lytic bone lesions are common and bone marrow is infiltrated 
by plasma cells. To this day, his original description of clinical characteristics and 
laboratory abnormalities still forms the basis of the diagnosis of a distinct clinico-
pathologic entity, which bears his name, Waldenström macroglobulinemia.
Waldenström macroglobulinemia
Waldenström macroglobulinemia (WM) is a B-cell malignancy characterized by a 
monoclonal lymphoplasmacytosis, producing a monoclonal immunoglobulin M 
(IgM) paraproteinemia. Clinical manifestations are related either to infiltration of the 
bone marrow and organs by the monoclonal B-cells (anemia, thrombocytopenia, 
granulocytopenia, organomegaly), or to the effects of the IgM paraproteinemia (hy-
perviscosity, peripheral neuropathy).3 Lack of universally accepted diagnostic criteria 
makes it difficult to determine a precise incidence of this disorder. Nevertheless, it is 
believed that WM is 6 times less common than multiple myeloma, with an estimated 
incidence of 3.4 per million in males and 1.7 per million in females in the United 
States.4,5 WM is more common in whites and familial clustering of cases has been 
reported, suggesting a role for genetic factors.6
Median age of patients with WM at diagnosis is 64 years. Compared to other hema-
tological malignancies, the clinical course of WM is usually indolent. Generally the 
disease does not require immediate treatment. The median survival of patients with 
WM is 5 years and 10% of these survive beyond 15 years after diagnosis, indicating 
the variability in outcome for WM patients. Several retrospective studies have been 
undertaken to identify clinical parameters impacting on prognosis.7-11 Most studies 
show age, hemoglobin value and β2-microglobulin levels as strong predictors of 
survival. In recent years, the detection of characteristic cytogenetic abnormalities 
of the malignant clone has added prognostic information with regards to several 
hematological malignancies. Currently, for WM there is no cytogenetic abnormality 
that shows association with outcome.
Asymptomatic WM is diagnosed in one third of patients and is often referred to as 
‘smoldering’ WM. This group generally only needs expectant observation. Two thirds 
of WM patients need some sort of treatment during their course of the disease. Plas-
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mapheresis is effective if symptoms are attributable to the hyperviscosity syndrome 
(oronasal bleedings, retinal hemorrhages and neurological abnormalities). Anemia 
is the most common indication for initiation of start systemic treatment. Several 
systemic therapies are available for first-line treatment: alkylating agents, nucleoside 
analogs and anti-CD20 monoclonal antibodies (rituximab). Often these regimens are 
combined with corticosteroids, which seem to be particularly useful in patients who 
develop auto-immune hemolytic anemia, mixed cryoglobulinemia or cold agglutinin 
disease, but have no additional effect on survival or response rate. Small numbers of 
patients have received autologous/allogeneic stem cell transplantation, but further 
evaluation of such therapies is needed and is currently only considered in refractory 
or relapsing disease. Sometimes painful splenomegaly or hypersplenism requires 
splenectomy.12
the clonal b-cell in Waldenström macroglobulinemia
The pathologic designation for WM is lymphoplasmacytic lymphoma, as defined by 
the Revised European-American Lymphoma classification and WHO criteria.13 This 
means that pleiomorphic B-lineage cells are found in WM bone marrow samples 
displaying a spectrum of morphologic features of small lymphocytes, plasmacytoid 
lymphocytes and plasma cells. A consensus panel at the Second International Work-
shop on WM in 2002 refined the clinicopathological diagnosis of WM as character-
ized by bone marrow infiltration by lymphoplasmacytic lymphoma, together with a 
monoclonal IgM protein of any concentration.14
Analysis of the immunoglobulin variable region (V) gene sequences and immuno-
phenotyping has helped to determine the origin of the malignant B-cell clone in WM. 
V-genes encode antigen specificity and increase of affinity can be established by a 
mechanism called somatic hypermutation. This somatic hypermutation takes place 
in the follicular germinal centre of peripheral lymphoid tissue, normally after antigen 
exposure. The variable region of the immunoglobulin heavy chain (V
H
) in WM shows 
that somatic hypermutation has taken place and that intraclonal heterogeneity is ab-
sent, which indicates that the WM B-cell is of (post)-germinal monoclonal origin15,16. 
After somatic hypermutation, a normal B-cell can either develop into a memory 
B-cell or undergo isotype class-switch recombination from IgM,IgD to IgG,IgA or 
IgE. WM B-cells do not undergo class-switch recombination. Recent reports reveal 
the potential of class-switch recombination in subsets of WM B-cells (in vitro and in 
vivo), which suggests an intact class-switch recombination machinery, but possible 
lack of appropriate stimuli17,18.
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Immunophenotyping has proven to be an essential part of diagnosis and clas-
sification of hematological malignancies. The immunophenotypic profile of WM 
cells include pan B-cell antigens CD19, CD20, CD22, CD79 together with surface 
IgM in virtually all cases.13,19 Surface markers CD5, CD10 and CD23 are helpful to 
distinguish B-cell malignancies, chronic lymphocytic leukemia, follicular lymphoma 
and mantle-cell lymphoma. In WM CD5 and CD10 expression seem to be uncommon 
and CD23 expression was found in 35%-61% of cases, often showing co-expression 
with CD5 and CD10.20 Expression of CD25, CD27, FMC7, BCL-2 and CD52 is seen 
regularly. CD103 is never expressed and CD138 expression, a plasma cell marker, is 
seen rarely.
Conventional cytogenetic analysis has revealed many disease specific chromosomal 
abnormalities in hematological malignancies and, especially in acute leukemia. These 
aberrations are of pathophysiologic, diagnostic and prognostic importance. Also, 
in several B-cell malignancies, such as multiple myeloma, chromosomal transloca-
tions at the immunoglobulin heavy chain locus (chromosome 14q32) are commonly 
seen.21-23 Translocations result in the fusion of genes that as a result of the structural 
consequences may express abnormal function or as the result of their location under 
another promoter may become abnormally expressed. For instance, the chromo-
somal translocation involving 14q32 generally results in deregulation of oncogenes 
located at four partner chromosomes such as, MMSET and FGFR3 (both on 4p16), 
CCND1 (on 11q13), CCND3 (on 6p21) and c-Maf (on 16q23). Other frequently found 
cytogenetic abnormalities were deletions of chromosome 13 and 17p which involves 
the loss of genetic material.24 Unfortunately, due to the low mitotic index of WM 
cells, informative karyotype studies have remained comparatively scarce.
In recent years new cytogenetic techniques have elucidated pathogenetic mecha-
nisms, have been useful for characterizing biologically distinct subtypes and have 
contributed to the development of risk-stratified treatment in various hematological 
malignancies.
Fluorescence in situ hybridization (FISH) is a technique that can overcome the 
problems of karyotyping in non-dividing cells as it allows for screening of large 
numbers of interphase cells for chromosomal abnormalities.25,26
High throughput array-based techniques are rapidly becoming the mainstay in 
genomic and proteomic analysis of human cancers nowadays. Together with the 
sequencing of the entire human genome, these techniques are able to screen for 
variability and aberrations at distinct cellular levels such as protein, RNA, micro-
RNA, single nucleotide polymorphisms, DNA and DNA methylation. In hematology, 
gene expression profiling using transcript microarrays has already provided interest-
ing insights in the distinction of different leukemia and lymphoma subtypes.27-29 
Knowledge of prognosis and biology of these different subtypes have resulted in 
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the development of subtype-specific treatment regimens which eventually could 
evolve in patient tailored treatment. Gene expression profiling may also generate 
new ideas about specific oncogenic pathways and steers new drug development 
toward targeted molecular therapy.
aims and outline of this thesis
The genetic basis of Waldenström macroglobulinemia entity is poorly understood 
and no genetic marker is available for this disease. Cytogenetic techniques have 
become available that allow for the analysis of genetic aberrations in non-dividing 
cells.
This thesis describes the characterization of the genetic profile of WM. In chapter 2, 
the prevalence and clinical consequences of two common cytogenetic aberrations 
is investigated for WM. These aberrations are known to be of clinical relevance in 
other related B-cell malignancies such as multiple myeloma, chronic lymphocytic 
leukemia and follicular lymphoma. Chapter 3 studies the presence of chromosomal 
translocations involving the immunoglobulin heavy chain locus in WM. Also the 
ploidy-status was assessed. In addition a new common aberration (deletion) for WM 
was detected. The prevalence of this new common aberration was subsequently 
investigated in IgM monoclonal gammopathy of undetermined significance (MGUS) 
(a precursor state to WM) (chapter 4). In chapter 4 the incidence of a minimal region 
of deletion in WM was also studied. The clinical impact of this deletion for WM 
patients is discussed in chapter 5. Finally, chapter 6 describes the comparison of WM 
with multiple myeloma, chronic lymphocytic leukemia and normal B-cells by gene 
expression profiling.
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abstract
Waldenström macroglobulinemia (WM) is a plasma cell (PC) dyscrasia characterized 
by a monoclonal IgM paraproteinemia. Deletions of 17p13.1 and 13q14 are associated 
with tumor progression and worsened outcome in multiple myeloma (MM), and we 
thus investigated WM patients for their presence. Patients (n=40) were required to 
have a ≥ 1.5g/dL serum IgM paraproteinemia and a monoclonal lymphoplasmacytic 
infiltrate. We used interphase fluorescence in situ hybridization (FISH) with probes 
that localized to 17p13.1 (LSI p53/CEP 17) and 13q14 (D13S319 and LSI 13 Rb). Of 40 
successfully studied patients for 17p13.1 (p53) deletions, 6 were abnormal, consis-
tent with hemizygous deletion (15%). Of 37 cases successfully studied for the 13q14 
deletions, 6 were also abnormal with one pair of signals deleted (16%). Patients 
with deletions were more likely to be later in the course of the disease. No obvious 
clinical associations were noted with the exception that patients with 17p13.1 (p53) 
deletions had a higher percent involvement of clonal cells in the BM. Deletions of 
these two regions are uncommon in WM, being more common in the late stages of 
the disease, thus unlikely playing a role in primary disease pathogenesis.
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introduction
Waldenström macroglobulinemia (WM) is an indolent B-cell malignancy, character-
ized by lymphoplasmacytic clonal cell involvement of the bone marrow (BM) and an 
associated IgM paraproteinemia 1,2. While WM has clinical and pathologic similarities 
to multiple myeloma (MM), there is little understanding of its disease pathogenesis. 
The median survival of patients averages 5 years 1,2. Ages of 65 or older, albumin 
less than 4.0 g/dL, presence of cytopenias or cryoglobulinemia, weight loss and 
hepatomegaly have all been proposed as prognostic factors 3,4. There is no known 
correlation between variables specific to the clonal cells and prognosis. It would be 
desirable to identify patients at risk of early progression and thus in need of closer 
surveillance or treatment.
Genomic deletions of the p53 tumor-suppressor-locus (17p13.1) have been observed 
in about 10% of patients with MM as detected by interphase fluorescence in situ 
hybridization (FISH), and are thought to negatively influence prognosis 5,6. Similarly, 
deletions at 13q14 are detected in about 50% of patients with MM when studied by 
interphase FISH and appear to be associated with a shortened survival 7-10. Inter-
phase FISH deletions of 13q14 commonly indicate large deletions of the q-arm or 
monosomy 9,11, and no area of minimal deletion has been identified in MM 12. There 
is no proven pathogenetic role for either deletion in the PC dyscrasias, but both 
are present in the large majority of clonal cells when detected, suggesting clonal 
selection 6-9,11. Deletions of these two sites in MM are suspected to be associated with 
progression of the disease as they increase in prevalence with advancing stages of 
the disease 6-9,13. Because deletions of 13q14 and 17p13.1 have been shown to be 
of prognostic significance in MM, and no systematic study of them in WM has been 
performed, we wanted to assess patients for their prevalence.
Patients and methods
Patients and bone marrow samples
We studied a total of 40 patients, who fulfilled the clinical and pathological diag-
nosis of WM 1,2. Patients were required to have an IgM monoclonal protein of at 
least 1.5 g/dL, by serum protein electrophoresis and/or nephelometry, and a clonal 
lymphoplasmacytic infiltration comprising at least 20% of the BM cellularity. Patients 
were also eligible if they had a monoclonal IgM greater than 3 g/dL and lower 
percentage BM involvement as could be seen in previously treated patients.
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Figure 1. The normal and abnormal patterns of hybridization for both the 13q14 and 17p13.1 (p53) probes. Each one of 
the images depicts both nuclei as observed in the drop slides (left) and a cell with the immunofluorescent detection of the 
cytoplasmic IgM (cIg-FISH) (right). (A) and (B) show the normal pattern of hybridization with the 17p13.1 (p53) probe (red) and 
CEP 17 (green) probes. (C) and (D) show the abnormal pattern observed in the cells with hemizygous deletion of 17p13.1 (p53) 
but with two remaining CEP 17 signals indicative of disomy. (E) and (F) show clonal cells with the normal pattern consisting 
of two pairs of hybridization signals for LSI 13 (Rb) (green) and D13S319 (red). (G) and (H) show samples with hemizygous 
deletion of the 13q14 locus and displaying only one pair of signals. (Images captured with the Leica DMR-XA microscope and 
the Leica Q-FISH imaging software, ×100 magnification.)
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The study was conducted under IRB approval, and samples were obtained from all 
cases at the time of routine clinical procurement. In 24 cases, fresh BM aspirates 
were enriched for mononuclear cells by the Ficoll method and 15 of these samples 
were further enriched by concurrent positive selection with CD138 and CD19 posi-
tive magnetic beads (Miltenyi Biotec). Cytospin slides were made to preserve the 
cytoplasm of cells and thus their morphology. In an additional 16 patients stored 
BM samples, previously cultured for metaphase analysis and arrested in mitosis with 
Colcemid, were available for study. A single drop of BM mononuclear cell suspen-
sion was dropped on a microscope slide for these specimens.
Cytoplasmic staining
In the 24 cases where cytospin slides were available we also performed cytoplasmic 
immunoglobulin (cIg) staining using an AMCA conjugated anti-IgM antibody (Vector 
Laboratories Inc.) in a variation of our previously published technique14. Cytospin 
slides were fixed in 95% ethanol for 5 minutes and incubated with an anti-IgM 
antibody in the dark for 20 minutes. The slides were washed and incubated with an 
AMCA-labeled anti-goat antibody. Slides were washed in 1X PBD and incubated in 
2% paraformaldehyde for 5 minutes. Each cytospin slide was subjected to an enzyme 
treatment of either proteinase K (10 μg/ml) for 15 minutes, or a 0.1% pepsin solution 
at 37°C for 2 minutes. The slides were then passed through an ethanol series (70%, 
80% and 100%).
Interphase FISH
We used the combination of a 17p13.1 probe labeled in Spectrum Red, (LSI p53, Vy-
sis Inc) probe simultaneously hybridized with a chromosome 17 alpha-satellite-DNA 
centromere probe (labeled in Spectrum Green, CEP17, Vysis Inc.). To test for 13q14 
deletions we used the commercially available probes LSI 13 (Rb) (Spectrum Green) 
and D13S319 (Spectrum Red, Vysis Inc.) (Figure 1). The normal pattern for cells was 
that of two pairs of signals (2R2G). Loss of one or more signals was indicative of 
deletion (2R1G, 1R2G, or 1R1G).
These probes have been extensively tested and produce discrete signals at the ex-
pected hybridization sites in normal metaphases, and a pair of discrete signals in 
interphase FISH cells. The upper limit of normal (ULN) value was calculated using 
the mean plus three standard deviations of 1000 normal cells. A patient was said to 
have a deletion if the percentage of cells with one signal exceeded the mean plus 
three standard deviations of normal. The ULN was estimated at 6% but to further 
improve in our specificity we arbitrarily decided to consider a sample as abnormal 
only if the cells with only one signal exceeded 10%. This is in agreement with our 
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experience with other assays currently used, as for similar (two color, centromere and 
locus specific probes) interphase FISH, the normal range cut off at 95% confidence 
interval for deletion is 8.5% (S. Jalal, personal communication).
We intended to score at least 100 clonal cells of each case, additionally identified by 
morphologic features and cytoplasmic anti-IgM staining in selected (n=24) cases. In 
all cases, but two, we could score 100 cells (50 cells in one patient for the 13q dele-
tion assay and 70 cells in one patient for the 17p13.1 deletion assay). The estimated 
percentage of clonal cells with deletions in the cytospin samples were the actual 
number of cells with deletion, because the cells are scored only if they were cIg-
positive. The estimated percentage of clonal cells for the drop slides was calculated 
by dividing the percent of total cells with only one signal by the percentage of BM 
involvement by the clonal cells.
Images were captured using a Leica epi-fluorescence microscope with a fluoroiso-
thiocyanate, Texas red, and a DAPI filter and the Leica Q-FISH software (Leica, 
Wetzlar, Germany). Images were processed using the Adobe Photoshop software 
(Adobe Systems Inc., Seattle, WA) and printed using a color laser printer (Tektronix 
Phaser 840, Wilsonville, OR, USA).
Statistical analysis
The χ2 test was used to compare patients and nominal variables. The Wilcoxon 
non-parametric test was used to compare continuous variables. The Wilcoxon and 
log-rank test were used to evaluate the difference in survival between patients with 
and without the abnormalities. Multiple comparisons were done with the most 
important prognostic and biologic variables. The following variables were studied 
both as continuous variables and as dichotomous variables (in parenthesis, and 
using the previously published prognostic models in WM); BM involvement, age 
(≥ 65 versus others), hemoglobin (≥ 12g/dL versus others), albumin (≥ 4g/dL versus 
others), creatinine, white blood cell count (≥ 4,000 X 106/L versus others), platelet 
count (≥ 150,000 X 106/L versus others), serum calcium, M-spike (≥ 2.5g/dL versus 
others), nephelometric serum IgM level (≥ 2.5g/dL versus others), β
2
-microglobulin 
(≥ 2.7 mg/dL versus others), serum viscosity, labeling index, gender, and previ-
ous treatment. The methods of Kaplan and Meier were used to perform a survival 
analysis.
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results
A total of 40 patients were studied and their clinical features are shown in Table 1. 
The median follow-up time since diagnosis was 52 months (range 2-209 months). 
At last follow-up 32 patients were alive with disease and 8 patients had died. The 
samples were obtained at diagnosis in 11 patients and later in the course of the 
disease in 29 patients.
Deletion of 17p13.1
We studied 40 patients for deletions of 17p13.1 (p53) and were successful in 24 
cytospin cases and in 16 cases with cell suspensions. A total of 6 cases showed an 
abnormal pattern indicative of hemizygous deletion (15%). (Table 2) In these 6 cases 
the pattern was that of an interstitial deletion with loss of one 17p13.1 (p53) signal 
and two remaining CEP17 probe-signals. The estimated median-percentage of clonal 
cells with only one signal was 67% (range 29-95%). Only one of these 6 patients had 
the 17p13.1 (p53) deletion detected at the time of diagnosis and in the remaining 5 
patients the samples were obtained later in the course of the disease.
Deletion of 13q14
We successfully studied 37 patients for 13q14 deletions (22 with cytospin slides and 
15 with cell suspension dropped slides). A total of 6 cases were found to have a 
Table 1. Clinical and laboratory features of patients studied
features median (range)
Patient age
patients aged ≥65
63 (45-82)
40%
Male (%)
Female (%)
24 (60%)
16 (40%)
Hemoglobin (g/dL)
patients with hemoglobin <10 g/dL
9.6 (5.2-14.8)
42.5%
Serum monoclonal spike (g/dL) 3.14 (0.67-6.9)
Nephelometric IgM (mg/dL) 4678 (1530-14260)
Percentage clonal cells in the BM 40 (10-95)
β2-microglobulin (mg/dL) 3.11 (0.15-6.89)
Viscosity (cpm) 2.6 (1.2-11)
Patients with known prior exposure to alkylator treatment (%) 21 (53)
Patients with leukopenia (%)1 11 (28)
Patients with thrombocytopenia (%)1 12 (30)
Patients with hepatomegaly (%) 1 (3)
Patients with splenomegaly (%) 5 (13)
1 Leukopenia was defined as a white blood cell count of less than 4,000×106/L and thrombocytopenia was defined as a platelet 
count of less than 150,000×106/L.
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pattern indicative of hemizygous deletion (16%) (Table 2). The estimated median-
percentage of clonal cells with only one signal was 75% (range 25-100%). In all cases 
there was concomitant loss of one pair of signals suggesting large deletions at 13q14 
or monosomy. Only one of 6 patients had the 13q14 deletions detected close to the 
time of diagnosis (4 months from the time of original diagnosis) and in the remaining 
5 patients the samples were obtained later in the course of the disease.
There was no association between having deletion of 13q14 and 17p13.1 (p53) as 
only one patient had deletions of both sites. To ensure that we were scoring the cor-
rect number of signals for both probes we also used six chromosome enumeration 
probes to asses ploidy status and found that in all cases the clonal cells were mostly 
diploid.
Clinical correlations
The only significant association was that patients with 17p13.1 (p53) deletion had a 
significantly higher percentage of BM involvement by the clonal process (mean 38% 
versus 75%, Wilcoxon p=0.002). Deletions of 17p13.1 (p53) appeared to be more 
common among women (deleted in 5/16 women versus 1/24 of men, Fisher’s exact 
test p=0.029). Patients with deletions of 17p13.1 (p53) were more likely to have 
received prior therapy than others (6/6 versus 15/29, Fisher’s exact test p=0.06). 
Patients with 13q14 deletions were more likely to have a platelet count of less than 
150,000 X106/L than others (Fishers exact p=0.052). There was a trend for patients 
Table 2. Percentage of clonal cells with deletions for 17p13.1 (p53) and 13q14
17p13.1 (p53) 13q14
Patient sample % bm 
involvement
status % 
abnormal 
cells
status % 
abnormal 
cells
% estimated 
clonal cells 
with deletion
17p13.1 deletions
1 Cytospin 95 deleted 95 unsuccessful 95
2 Cytospin 90 deleted 29 unsuccessful 29
3 Drop slide 40 deleted 38 normal 1 95
4 Drop slide 70 deleted 47 normal 3 67
5 Drop slide 90 deleted 40 normal 0 44
17p13.1 and 13q14 deletion
6 Drop slide 70 deleted 46 deleted 33 66/47 a
13q14 deletions
7 Cytospin 30 normal 2 deleted 98 98
8 Cytospin 80 normal 4 deleted 96 96
9 Cytospin 20 normal 2 deleted 53 53
10 Cytospin 30 normal 3 deleted 25 25
11 Drop slide 55 normal 2 deleted 55 100
a values for 17p13.1 and 13q14 deleted cells, respectively.
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with 13q14 towards a higher serum IgM level and a higher β
2
-microglobulin (p= 
NS). Survival since the time of diagnosis was not clearly different when patients 
were stratified according to the presence or absence of deletions at either 13q14 
or 17p13.1 (p53). Patients with deletions of 17p13.1 (p53) were more likely to be 
dead at the time of last follow-up as compared to others (4/6 versus 5/34, Fisher’s 
exact p=0.0163). However no conclusive comments can be made with regards to 
these observations because of the heterogeneous nature of the patients and manage-
ment strategies, the small number of events, and different time of detection of the 
chromosomal abnormalities (at diagnosis versus later).
discussion
In this study we have shown that deletions of 17p13.1 (p53) and 13q14 are uncom-
mon in the clonal cells of patients with WM. The low frequency of these deletions 
is in agreement with what would be expected for an indolent clonal B-cell disorder 
such as WM. Furthermore, it should be noted that both deletions were almost exclu-
sively seen in the advanced stages of the disease and not at the time of diagnosis. 
This particular study cannot be used to examine the influence of deletions at 13q14 
and 17p13.1 (p53) on survival because of the aforementioned reasons. The study 
of a much larger number of patients is needed to evaluate the possible prognostic 
significance of deletions at these two sites. However with such a low prevalence 
of the abnormality in the newly diagnosed patients these studies are likely to be 
noncontributory.
The deletion prevalence of 17p13.1 (p53) (~15%) is similar to what we and others 
have observed in the clonal cells of MM patients (R. Fonseca, manuscript in prepara-
tion) 15, and also increase in frequency with disease progression. The incidence of 
13q14 deletions is less than that commonly reported in B-cell chronic lymphocytic 
leukemia 16-25 (CLL) and MM 7-10. As with 17p13 deletions, those of 13q14 are also 
uncommon at the time of diagnosis. These facts attest to a different biologic nature 
of WM as compared to MM or B-cell CLL.
The two chromosomal abnormalities are unlikely to play a role in the etiology of the 
disease and it is currently unknown whether loss of DNA at these regions contributes 
in a mechanistic fashion to progression. Since these deletions usually afflicted the 
majority of the clonal cells, as is seen in MM 9,11, they appear to be evolutionary 
selected. This would imply that these abnormalities are seen in a minority of cells at 
the time of diagnosis or are acquired with progression and ultimately the percentage 
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of abnormal cells progressively increases with clonal growth. It is also possible that 
deletions of these two sites are merely reflective of ongoing genomic instability26, 
or that they were present since the clone origin and persist through its evolution, 
although this seems less likely given their higher prevalence in the more advanced 
cases. The sensitivity of our assays and the limited number of patients studied do not 
allow us to reach firm conclusions. We propose that deletions at 13q14 or 17p13.1 
(p53) do not contribute to the early stage pathogenesis.
The underlying pathogenetic mechanisms responsible for WM are unknown. We 
have recently shown that patients with WM harbor no 14q32 translocations including 
the t(9;14)(p13;q32) as has been reported in the non-secretory lymphoplasmacytic 
lymphomas. The few reported series would suggest that aneuploidy is not common 
although few studies have addressed this issue in detail. The search for the underly-
ing molecular lesion responsible for disease pathogenesis must continue.
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abstract
Lymphoplasmacytic lymphoma (LPL) is characterized by t(9;14)(p13;q32) in 50% of 
patients who lack paraproteinemia. Waldenström macroglobulinemia (WM), which 
has an immunoglobulin M (IgM) paraproteinemia, is classified as an LPL. Rare re-
ports have suggested that WM sometimes is associated with 14q23 translocations, 
deletions of 6q, and t(11;18)(q21;q21). We tested for these abnormalities in the clonal 
cells of WM patients.
We selected patients with clinicopathologic diagnosis of WM (all had IgM levels 
greater than 1.5g/dL). Southern blot assay was used to detect legitimate and illegiti-
mate IgH switch rearrangements. In addition to conventional cytogenetic (CC) and 
multicolor metaphase fluorescence in-situ hybridization (M-FISH) analyses, we used 
interphase FISH to screen for t(9;14)(p13;q32) and other IgH translocations, t(11;18)
(q21;q21), and 6q21 deletions. Genomic stability was also assessed using chromo-
some enumeration probes for chromosomes 7, 9, 11, 12, 15 and 17 in 15 patients.
There was no evidence of either legitimate or illegitimate IgH rearrangements by 
the Southern blot assay (n=12). CC (n=37), M-FISH analyses (n=5), and interphase 
FISH (n=42) failed to identify IgH or t(11;18) translocations. Although tumor cells 
from most patients were diploid for the chromosomes studied, deletions of 6q21 
were observed in 42% of patients.
In contrast to LPL tumors that are not associated with a paraproteinemia and have 
frequent t(9;14)(p13;q32) translocations, IgH translocations are not found in WM, a 
form of LPL tumor distinguished by an IgM paraproteinemia. However, WM tumor 
cells, which appear to be diploid or near diploid, often have deletions of 6q21.
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introduction
Waldenström macroglobulinemia (WM) is a B-cell lymphoproliferative disorder char-
acterized by an immunoglobulin M (IgM) paraproteinemia and the accumulation of 
clonal lymphoplasmacytic cells in the bone marrow (BM)1,2. With advancing disease, 
patients may develop organomegaly, anemia and hyperviscosity. A serum monoclo-
nal IgM that exceeds a concentration of 1.5 g/dl is characteristic of WM, and is use-
ful in differentiating WM from other neoplasms with plasmacytoid differentiation3. 
The diagnosis is based on the presence of the characteristic accompanying clinical 
features and the pathologic findings, most commonly from the bone marrow (Table 
1). Because of its morphologic and immunophenotypic features, the pathologic 
designation for WM has been lymphoplasmacytic lymphoma (LPL), as proposed by 
the revised European-American lymphoma classification 3. Because LPL is not always 
associated with paraproteinemia, it is possible that LPL without paraproteinemia and 
WM (LPL with IgM paraproteinemia) are distinct pathological entities.
It has been reported that the t(9;14)(p13;q32) translocation occur in at least 50% 
of patients with LPL 4. The t(9;14)(p13;q32) results in up-regulation of PAX-5 5,6, 
implicating this gene as a putative oncogene in the pathogenesis of LPL 7-9. Other 
PAX genes are known to be involved in diverse human neoplasia 10. PAX-5 encodes 
for the transcription factor, B-cell specific activation protein (BSAP), which is a 50-kD 
protein critical for B-cell development. BSAP up-regulation appears to cause an 
increase in B-cell proliferation 11 and is characteristically absent in both normal and 
malignant plasma cells 12-15. BSAP/PAX-5 is known to down-regulate the Iε promoter 
and the IgH 3’α enhancer, with consequent down-regulation of IgH transcription 16-19. 
In the original series of LPL tumors with the t(9;14)(p13;q32) translocation, none of 
Table 1. Clinical and laboratory features of patients
characteristic all Patients
n=74 %
gender male
   female
46
28
63
37
light chain type κ
     λ
     biclonal
55
18
1
74
24
2
β2-microglobulin > 2.7 (mg/L) 24 of 39 62
albumin < 3.5 (n = 46) (g/dL) 23 of 46 50
labeling index 1 * (%) 1 2
hemoglobin < 11 (g/dL) 47 of 73 64
bm clonal involvement (%) 50 (median) 5-95 (range)
* Includes plasma cells and lymphocyte clonal cells (defined by light chain restriction).
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the patients had paraproteinemia, a finding that is consistent with the possibility that 
overexpression of PAX-5 prevents the expression of high levels of immunoglobulin 
that result in paraproteinemia. If this hypothesis is correct, one would expect that 
the t(9;14)(p13;q32) translocation would not be present in WM, a form of LPL with 
an IgM paraproteinemia.
The underlying genetic abnormalities responsible for WM have not been identi-
fied. From a limited number of conventional cytogenetic (CC) studies, no recurrent 
cytogenetic abnormalities have been detected in tumor cells from patients with WM. 
However, there are sporadic reports of WM tumors with IgH or t(11;18)(q21;q21) 
translocations or 6q abnormalities, each of which occurs in other kinds of B-cell 
tumors. Thus, we decided to test a cohort of patients with well-defined WM to 
address 3 issues. First, despite the expression of IgM in WM, does legitimate or il-
legitimate IgH switch recombination occur, and perhaps mediate IgH translocations, 
as previously shown in multiple myeloma and other B cell tumors?20 Second, using 
a highly sensitive and specific interphase fluorescence in-situ hybridization (FISH) 
assay, what is the incidence of the t(9;14)(p13;q32) or other IgH translocations in 
WM? Third, through a combination of CC, multicolor metaphase fluorescence in-situ 
hybridization (M-FISH), and interphase FISH assays, what is the incidence of recur-
rent numeric or structural karyotype abnormalities – including the t(11;18)(q21;q21) 
translocation or abnormalities of 6q21 – in WM?
Patients and methods
Patients and bone marrow samples
We identified patients who fulfilled the clinical and pathological diagnosis of WM 1,2 
(Table 1). The study was conducted under institutional review board approval. Each 
patient was required to have an IgM paraproteinemia of 1.5 g/dL or greater and 
clonal lymphoplasmacytic infiltration comprising at least 20% of the mono nuclear 
cells in the bone marrow (BM), but BM involvement could be lower (10% to 19%) 
if the patient’s monoclonal protein exceeded 3 g/dL. The cohort consisted of 74 pa-
tients who fulfilled these criteria (65% had prior chemotherapy exposure). Samples 
available for study included BM aspirate samples obtained from 33 cases at the 
time of routine clinical procurement (all studies with cIg-FISH), Fixed cell pellets in 
Carnoy fixative and cultured for the purpose of clinical karyotype analysis from 17 
patients, or both types of samples from 24 patients (cultured and fixed cell pellets 
and uncultured bone marrow aspirate).
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In 19 patients, bone marrow research aspirates were further enriched by simultane-
ous CD138+ and CD19+ magnetic bead selection (Miltenyi Biotec, Auburn, CA). 
Owen et al21,22 have found that clonal cells in WM express CD19, CD138 or both. 
Because of the pleomorphic nature of the clonal process in WM, we felt that with 
the combination of CD138 and the B cell marker CD19, we could enrich for the 
clonal cells of patients. When we only had stored BM samples previously cultured 
for metaphase analysis, it was not possible to perform magnetic bead selection or 
concurrent immunofluorescent staining of the cytoplasmic immunoglobulins.
This study was conducted under the approval of the Mayo Clinic institutional review 
board, and patients gave informed consent for the sample collection. The study was 
conducted in accordance with the Declaration of Helsinki for research with human 
subjects.
Southern blot
The Southern blot analysis was performed according to our previously published 
technique 20. In brief, we used a J
H
 probe to detect the germ line and clonal bands 
to ensure the presence of clonal DNA. We subsequently performed sequential hy-
bridization with probes flanking the 5’ and the 3’ends of the Sµ switch region. The 
presence of fully concordant 5’Sµ and 3’Sµ bands indicates the absence of IgH switch 
recombination. Alternatively, discordant 5’Sµ and 3’Sµ bands that do not hybridize 
with other IgH switch probes strongly suggest illegitimate IgH switch recombination 
caused by a chromosomal translocation20. A total of 2.5-10 µg of total BM DNA (these 
samples were not magnetic micro-bead enriched) was loaded into each well after 
complete digestion with restriction enzyme HindIII. (Figure 1)
Standard cytogenetic analysis
Conventional karyotypes performed for clinical evaluation were available for 37 
patients. BM specimens were processed by both direct and short-term culture tech-
niques, as described previously 23. At least 20 banded metaphases were analyzed for 
each patient, with representative karyotypes prepared from at least 2 metaphases 
from each clone. The karyotype was described according to the International System 
for Human Cytogenetics Nomenclature (ISCN, 1995).
Multicolor-FISH assay
M-FISH was performed as previously described.24,25 Slides with informative karyo-
types in 5 cases were processed using the Spectra Vysion (Vysis, Downer’s Grove, 
IL) reagent. Probes for M-FISH were placed on the hybridization site, protected 
with a coverslip, sealed with rubber cement, and placed in the HYBrite (Vysis) 
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for co-denaturation. Slides were viewed with a Zeiss (Thornwood, NY) microscope 
powered by a 100-W mercury bulb. Filter sets for capturing M-FISH images and 
viewing metaphases were from Vysis.
Interphase FISH
We used 2 different probe strategies to detect IgH rearrangements by interphase 
FISH. We first used a break-apart strategy (segregation), using a cosmid probe (V
H
) 
(labeled red) specific for the IgH variable region and a BAC clone (C
H
) specific for 
the IgH constant (labeled green) 26. Under separate experiments and to detect the 
t(9;14)(p13;q32) translocation, we used a fusion strategy (colocalization), using a 
BAC clone (clone 112gO2; Incyte Genomics, Palo Alto, CA) specific for the PAX-5 
gene at 9p13 (labeled red) (Figure 2) together with the V
H
/C
H
 probes (both labeled 
in green). 26 To validate these probes, we tested them in the cell line KIS-1, which 
harbors the t(9;14)(p13;q32) and was kindly provided by Dr Hitoshi Ohno (Kyoto 
University, Japan) and in a patient sample with t(9;14)(p13;q32) kindly provided by 
Dr Herve Avet-Loiseau (Nantes, France). In both cases our probes showed 2 fusion 
signals of the IgH probe and the PAX-5 BAC clone, on both derivative chromosomes 
in each case, indicating its usefulness for detection of this translocation.
 
Figure 1. Southern blot assay used to detect legitimate and illegitimate rearrangements at the IgH locus. Southern blot of 4 
WM samples that were fractionated on an agarose gel, blotted, and hybridized sequentially with a JH probe (A), and a 5’ Sµ 
probe (B).  Horizontal bars at the left of each exposure correspond to λ HindIII markers, with the 9.4-kb marker in each lane 
but the 6.6-kb marker included for panel A.  Panel A shows the genomic DNA probes with a JH  oligonucleotide probe, and the 
corresponding clonal bands (variable size) and germline fragments (approximately 10 kb).  Panel B shows the constant size 
of the 5’ Sµ probe indicating lack of legitimate or illegitimate rearrangements.  The total amount of genomic DNA loaded was 
2.5 µg per lane.
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To detect t(11;18)(q21;q21) we used a set of probes, kindly provided by Dr David 
James (Mayo Clinic), that span both breakpoints in all reported t(11;18)(q21;q21) 
translocations and that result in a double fusion, as validated by E. Remstein et al 27 
(Figure 2). To screen for possible aneuploidy, we used commercially available cen-
tromere enumeration probes (CEPs) for chromosomes 7, 9, 11, 12, 15 and 17 (Vysis). 
To screen for 6q21 deletions we used the clone RPCI 91C23 (obtained form Oakland 
Childrens Hospital, CA) with simultaneous hybridization for CEP 6. This same cohort 
of patients has also been studied for deletions at 13q14 and 17p13 by interphase 
FISH and the results are compared to those obtained from this study 28.
Noncommercial probes were directly labeled using standard nick translation with 
SpectrumRed or SpectrumGreen (Vysis). Slides and probes were co-denatured for 
7 minutes at 80°C, placed in a humidified chamber and allowed to hybridize in a 
 
Figure 2. Correct localization of the probes used for the detection of the t(9;14)(p13;q32) and the t(11;18)(q21;q21). (A) 
Localization of the PAX-5-specific probe to chromosome 9 at band p13 (red). The green signal is that of chromosome 4 
centromeric probe. (B) Normal pattern of hybridization for the IgH/PAX-5 probes, consistent with 2 pairs of discrete green and 
red signal, respectively, without fusion signals. (C) Metaphase FISH assay in a patient with known t(9;14)(p13;q32) serving 
as the positive control. Metaphase shows 2 fusion signals indicating a balanced reciprocal translocation and the germline 
configuration in for the IgH probes (green) and the 9p13 PAX-5 probe (red). Smaller boxes in the lower left corner depict an 
enlarged view with the der(14)t(9;14) chromosome, showing the fusion signal indicative of the translocation (right small box) 
and the same chromosome after stripping of the probes and hybridizing with whole chromosome paints (WCPs). Left small box: 
red indicates WCP 14, and green in WCP 9). (D) Interphase FISH results on the same patient and clearly show 2 distinct fusion 
signals indicative of the balanced translocation. (E) Correct localization of the probes utilized for the detection of the t(11;18)
(q21;q21). (F) Normal interphase FISH pattern for these same 2 probes, again consistent with 2 pairs of discrete green and red 
signal, respectively, without resulting fusion signals
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37°C oven overnight. Slides were then washed and an anti-fade mounting medium 
(Vectashield H-1000) was applied to each and coverslipped. For slides not assessed 
for the cytoplasmic immunoglobulin stain, DAPI (Vector Laboratories, Burlington, 
CA) was added to the medium.
Cytoplasmic staining
In all patients (n = 33) from which cytospin slides were available, we performed 
cytoplasmic staining of the IgM cytoplasmic protein using an AMCA (7-amino-3-
acetic acid)-conjugated anti-IgM antibody (Vector Laboratories), in a variation of our 
previously published technique 29. If we could not use the cIg-FISH technique, or if 
the original cytospin slides were depleted, we used slides made from the cultured 
and fixed cells. Because of these limitations these slides were scored on unselected 
cells without regard to cellular morphology.
Scoring statistics
Using a Leica epifluorescence microscope with a fluorescein isothiocyanate, Texas 
red, and a DAPI filter, we attempted to score at least 100 clonal cells from each 
patient. In the cytospin slides, only cells identified by morphologic features or cyto-
plasmic anti-IgM staining were scored. Fusion of probe signals (colocalization) was 
defined, as 2 probe signals making contact (Figure 2). Break-apart of probe signals 
(segregation) was defined by a distance of more than 3 signal widths between 2 
differently labeled probe signals. A sample was said to have an abnormal pattern if 
the percentage of cells exceeded the mean percentage background level plus three 
standard deviations found for normal cells. The mean percentage background was 
determined in normal and abnormal samples, and at least 1000 cells were scored for 
each set of probes.
results
Southern blot analysis
To detect IgH rearrangements we conducted a pilot study with the Southern blot 
analysis, but we did not find evidence of either legitimate or illegitimate IgH switch 
recombination fragments. In all cases the presence of clonal cell DNA was confirmed 
by the finding of clonal rearrangements by hybridization with a J
H
 probe, but there 
was complete concordance of the 5’Sµ and the 3’Sµ bands in sequential hybridiza-
tions (n = 12). (Figure 1)
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Conventional cytogenetics and M-FISH
We reviewed the karyotype results of 45 patients using conventional cytogenetic 
analysis performed for routine clinical purposes. Six patients were excluded because 
chromosomal analysis was performed at the time of diagnosis of secondary myelo-
dysplasia or leukemia. Abnormal findings on BM examination and resultant abnormal 
karyotypes were consistent with the diagnoses. Of the remaining 39 patients, 35 had 
sufficient number of metaphases to be evaluable (Table 2). Of these 35 patients, 22 
(63%) patients were found to have only normal metaphases, possibly originating 
from the normal myeloid elements in the BM, including 2 patients whose only 
abnormality was the loss of chromosome Y. Abnormal metaphases were obtained in 
13 (37%) patients, 5 of whom were not previously treated. Structural and numerical 
chromosomal abnormalities were encountered in the abnormal karyotypes, but usu-
ally we observed single abnormalities in an otherwise normal karyotype (Table 2). 
For the 13 patients with abnormal karyotype, 4 (31%) had recurrent abnormalities 
of chromosome 13, with del(13q14) in 3 and monosomy 13 in one; 2 (15%) had 
del(6)(q13q21)(q13q25); 1 (8%) had an addition at chromosome 6q27( add(6)(q27)): 
2 (15%) had abnormalities of chromosome 17q25 and 1 (8%) had chromosome 17 
monosomy; 2 had del(5q)(13q35) (one with and one without prior therapy); and 
4 had diverse abnormalities in chromosome 8 (t(Y;8)(q11;p23), i(8)(q10), der(8;9)
Table 2. Karyotypic abnormalities in patients with informative karyotypes
Patient Karyotype additional information provided by m-fish
[number of metaphases analyzed]
Patients not previously treated
1 ~4n with fragmentation[5]/46,XX [20] 48,XX,der(9),der(17) [8]
2 47,X,t(Y;8)(q11.2;p23),del(5)(q13q31), del(6)(q13q21),der(19)
t(19;?)(q13.1;?),+2mar [10]/ 46,XY [10]/10=
Not done
3 46,XX,del(6)(q13q25)[1]/46,XX [29] No further information [4]
4 46,XY,del(13)(q14q22)[2]/46,XY [18] 49X,-X+der(3),+4,der(9),+18,+19 [2]
5 47,X,-Y,add(3)(q21),add(4)(q21), add(6)(q27),add(7)(q11.2),i(8)
(q10),+10,-13,-13,-15, add(17)(q25),+add(18)(q23),+19,-
20,+3mar[cp3]/46,XY [17]
No further information [4]
Previously treated patients
6 47-48,XY,der(16)t(16;?)(q24;?),der(17) t(17;?)(q25;?),+1-2mar 
[5]/46,XY [14]
Not done
7 45,X,-X,der(8;9)(q10;q10),+9,-17,-19,+2mar[1]/ 45,idem,t(7;18)
(p15;q21)[1]/46,XX [28]
Not done
8 45,XY,-7[7]/46,XY [23] 45,XY,-7 [3]
9 46,XX,-12,+r[8]/46,XX [10] Not done
10 46,XX,del(13)(q14q22)[3]/46,XX [17] Not done
11 46,XX,del(13)(q12q14) [3]/46,XX [5] Not done
12 46,XY,+add(1)(p12),-15[1]/46,XY [29] Not done
13 47,XY,+8,?del(5)(q13q35),del(6)(p21.3?p23),tdic(13;?) [20] Not done
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(q10;q10) and -8). As a follow-up to conventional cytogenetics in 5 of 13 patients with 
an abnormal karyotype, M-FISH studies identified additional karyotypic abnormali-
ties in 2 patients but provided no additional information in 3 patients (Table 2).
Interphase FISH
Of the 31 patients studied, 30 had no evidence of IgH translocations by the V
H
/C
H
 
strategy, and one patient had 37% of cells harboring the abnormality. In addition, in 
none of these 31 patients could we find fusion signals indicative of t(9;14)(p13;q32) 
(Figure 2). When we extended our study to include 18 additional patients in whom 
we had CC cell suspension to study, we found that none of them had evidence of 
IgH translocations by the V
H
/C
H
 break-apart strategy (n = 17) or the t(9;14)(p13;q32) 
translocation by the fusion strategy (n = 18). One patient had 3 or more signals from 
the PAX-5 BAC clone in 69% of the cells but no fusions (17% with 3 signals, and 
52% with 4 signals). This same patient had evidence of trisomy for chromosome 9 in 
the metaphase analysis. None of the 24 patients studied had evidence of the t(11;18)
(q21;q21) as detected by FISH.
To screen for possible aneuploidy, tumor cells from 15 patients were studied by 
interphase FISH using CEP probes for chromosomes 7, 9, 11, 12, 15 and 17. With 
the exception of one patient, all chromosomes were normal; one patient had only 
one signal for chromosome 9, indicative of monosomy in 26% of the clonal cells. 
Although some patients showed abnormalities in the karyotype consistent with 
aneuploidy (Table 2), interphase FISH showed that this is the exception, and patients 
with karyotype abnormalities likely represent aggressive variants of the disease. 
There is probably an inherent bias in the patient population that is subjected to 
scrutiny of karyotype analysis (i.e., worsening disease). In addition it is highly likely, 
as in multiple myeloma, that the ability to obtain informative metaphases is closely 
related to the tumor burden and proliferative activity30.
Deletions of 6q
We also tested 24 patients (in whom we had metaphase culture slides but could not 
perform the cIg-FISH assay) for evidence of 6q21 deletions and found that 10 (42%) 
had abnormalities in more than 25% of the cells. In addition 5 (21%) more patients 
had between 10% and 25% abnormal cells. Because in many of these latter patients 
the percentage of clonal involvement of the bone marrow was between 10% and 
20%, it is conceivable that they could also have had deletions at this site. Therefore 
between 42% and 63% of patients had deletions of 6q21.
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Correlation between interphase FISH and karyotype analysis
Three patients had chromosome abnormality detected by metaphase analysis; we 
also performed specific interphase FISH testing. In one case of a patient –13 was 
confirmed by FISH, and in one patient with the deletion of 17p this was confirmed 
by FISH. In yet in another patient, del(6)(q13q25) was detected by our FISH probe.
discussion
In this study we have found that clonal cells from patients with clinically defined 
WM do not have the t(9;14)(p13;q32) translocation, as previously found in 50% of 
patients with LPL but without paraproteinemia. Thus, WM, a type of LPL with IgM 
paraproteinemia, and LPL with no paraproteinemia differ not only in phenotype but 
also in the presence of the t(9;14)(p13;q32) translocation. This result is consistent 
with the hypothesis that the predicted biologic features of B-cell clones with PAX-5 
up-regulation are incompatible with the phenotype of WM 17-19. Notably, BSAP is 
absent in plasma cells, and overexpression of PAX-5/BSAP abrogates the production 
of the J peptide. 13 This protein is an integral component of the IgM pentamers, 
which give rise to the hyperviscosity of patients with WM. 31 In addition, PAX-5/
BSAP negatively regulates the 3’α enhancer, with likely consequent inhibition of 
transcription at the IgH locus, 17-19,32,33 a result inconsistent with the IgM parapro-
teinemia observed in these patients. Finally, the inhibition of PAX-5 transcription 
with antisense oligonucleotide down-regulates immunoglobulin class switching 11, 
a result consistent with our failure to identify evidence for legitimate or illegitimate 
IgH isotype switch recombination in the clonal cells of IgM-producing WM.
Our finding that IgH translocations are not present in WM is consistent with the 
previously reported karyotypic abnormalities in these patients. In a series of 45 
WM cases reported by Louviaux et al, 12 patients had abnormal metaphases, but 
no abnormalities of chromosome 14 were noted 34. In our review of the cytogenetic 
database at the Mayo Clinic of patients we report here, which we report here, we 
were unable to find any patient with 14q32 abnormalities. Unlike multiple myeloma 
20,35,36 and low-grade lymphomas, 37,38 14q32 translocations appear not to be initiation 
events for disease pathogenesis in WM. Scattered reports in the literature describe 
patients with WM and 14q32 translocations, including t(8;14)(q24;q32). 39-42 Some of 
these reports are confounded either by the lack of consistent clinical features associ-
ated with a diagnosis of WM or by the samples originating from pleural effusions 
and, thus, of unknown relation to the original clone. 39-42
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There are rare reports of WM patients in whom the tumor cells had a t(11;18)
(q21;q21) translocation, 43,44 an abnormality also seen in approximately 20% of ex-
tranodal marginal zone lymphomas. 45 Because we have been unable to detect this 
translocation in the tumor cells of 24 WM patients, it must be, at best, rare.
Despite an apparent paucity of structural and numeric karyotypic abnormalities in 
tumor cells from our cohort of WM patients, we did identify a high prevalence of 
deletions of the long arm of chromosome 6. This is consistent with what has been 
previously reported by conventional cytogenetic studies in selected patients with WM 
46,47 and other B-cell neoplasias in which abnormalities in this region are common. 48-
50 This is also consistent with findings from our karyotype analysis that 3 patients had 
6q deletions. Further work is under way to characterize the area of minimal deletion, 
and the search for putative genes involved in disease pathogenesis. We suspect that 
the inactivation of a tumor suppressor gene at this locus, as is seen in other B-cell 
neoplasias, is likely to be of importance for clone immortalization.
Our data suggest less genomic instability in WM than in multiple myeloma, as 
determined by metaphase analyses for structural and numeric abnormalities and 
interphase FISH for numeric abnormalities. Moreover, we have recently reported 
that, unlike multiple myeloma and B-cell chronic lymphocytic leukemia (B-CLL), 
deletions of 13q14 are rarely observed at the time of diagnosis 28. As are deletions 
of 17p13.1 (see below), 13q14 deletions are seen mostly in advanced stages and in 
a small fraction (approximately 15%) of patients with WM at the time of diagnosis. 
28 Therefore, we can conclude that WM is clearly different from myeloma in that it 
lacks IgH translocations, has only infrequent deletions of 13q14, and has limited 
numeric and structural karyotypic abnormalities. WM is also different from B-CLL in 
the lower incidence of 13q14 deletions (seen in approximately 50% of patients with 
B-CLL) and the low prevalence of trisomy 12 (seen in approximately 15% of patients 
with B-CLL).51 WM is also different from the extranodal marginal zone lymphomas 
in that we could not detect any case with the t(11;18)(q21;q21). The lack of IgH 
translocations also differentiates WM from many kinds of B lymphomas (follicular, 
mantle cell, diffuse large cell).52 We thus conclude that the biologic nature of WM is 
different from multiple myeloma and most lymphomas, but appears more similar to 
post-germinal center B-CLL (Table 3).
The normal counterpart of the malignant cell in WM might be a postgerminal center 
IgM memory B cell that has undergone somatic hypermutation but fails to undergo 
isotype class switching. Our Southern blot results, failing to identify legitimate or 
illegitimate IgH switch recombination rearrangements indicative of isotype class 
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switching, and the presence of the IgM paraproteinemia are consistent with this. In 
addition, individual WM tumor cells show heterogeneous morphological features 
consistent with variable differentiation from a B cell to a plasma cell but failure to 
fully differentiate into plasma cells. We speculate that the presumed genetic event(s) 
responsible for generating an immortalized clone of tumor cells in WM are directly 
or indirectly responsible for the failure of isotype class switching and lack of dif-
ferentiation to plasma cells. With the exception of frequent deletions of the long arm 
of chromosome 6, our knowledge of specific primary or secondary genetic events in 
WM remains elusive.
Table 3. Genetic comparison between WM, myeloma and B-CLL
feature Wm myeloma b-cll
clinical course Usually indolent Aggressive Usually indolent
genomic stability (ploidy) Diploid Aneuploid Diploid
structural abnormalities (other than 6q) Infrequent Frequent, multiple Infrequent
igh translocations Rare 75% Rare
chromosome 13 abnormalities at 
diagnosis
Rare28 ~50% ~50%
deletions of 17p13 Rare at diagnosis28 Rare (10%-15%) Rare (5%)
Proliferation by the labeling index Low/absent Active Not done
somatic hypermutation Yes Yes Variable
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abstract
IgM monoclonal gammopathy of undetermined significance (IgM MGUS) and 
Waldenström macroglobulinemia (WM) are sometimes clinically difficult to distin-
guish. In our previous study, deletion of the long arm of chromosome 6 (6q) was 
found in about half of WM patients. To further clarify the area of minimal deletion at 
6q (6q-) and to address the issue of whether 6q- occurs in IgM MGUS, 12 IgM MGUS 
and 38 WM patients were studied by fluorescence in situ hybridization (FISH) using 
probes targeting different chromosomal segments of 6q. No 6q deletions were found 
in IgM MGUS samples. Of 38 successfully studied WM patients, 21 (55%) showed a 
deletion of 6q. The area of minimal deletion was between 6q23 and 6q24.3, but the 
deletion usually encompassed a large fragment of the 6q arm. These results indicate 
that 6q- can distinguish WM from IgM MGUS and is likely to be a secondary event.
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introduction
Waldenström macroglobulinemia (WM) is a B-cell lymphoproliferative disorder char-
acterized by the accumulation of monoclonal cells in bone marrow and peripheral 
lymphoid tissues and is associated with an IgM serum monoclonal protein 1. The 
pathology designation for WM is lymphoplasmacytic lymphoma (LPL), as proposed 
by the World Health Organization Classification of Tumours. We have reported that 
the most common genomic aberration in WM clonal cells is loss of the long arm 
of chromosome 6 (6q)2,3. As of yet, however, no minimal area of deletion and no 
unique gene expression consequences of these deletions have been identified. It is 
important to delineate the minimal area of deletion, which could harbor possible 
tumor suppressor genes (TSG). To do so we conducted a fluorescence in situ hybrid-
ization (FISH) study using a set of probes representative of different regions of 6q.
Likewise, it is currently unclear whether 6q- represents an early immortalizing 
genetic event or whether it is associated with disease progression. The study of 
6q in IgM monoclonal gammopathy of undetermined significance (IgM MGUS) can 
help elucidate this question. IgM MGUS is a precursor state to lymphoproliferative 
disorders, particularly WM. In a population based study we were able to show that 
patients with IgM MGUS have a 46-fold higher risk of developing Waldenström 
macroglobulinemia than the general population 4. In a Mayo Clinic series of 242 
patients with IgM MGUS, 40 (17%) developed malignant lymphoproliferative disor-
ders of which 22/40 (55%) developed WM5. During long-term follow up, the risk of 
progression of MGUS of IgM type to lymphoma or related disorders averaged 1.5% 
per year 6. Little is known about the biology of IgM MGUS and the factors associated 
with its malignant progression to WM.
Finally, the similarity of clinical presentation and laboratory parameters between 
IgM MGUS and Waldenström macroglobulinemia makes the discrimination of these 
two diseases difficult and the diagnostic criteria frequently overlap. An international 
consensus panel concluded that the level of the monoclonal protein alone could 
not be used as the sole discriminant between IgM MGUS and WM 7. Furthermore, 
cases with classic lymphoplasmacytic morphology in the bone marrow, even with 
low concentration of a serum monoclonal protein, have been classified as WM. It is 
evident that better markers are needed to make this diagnostic differentiation.
In the present FISH study we determine a more accurate prevalence of 6q- in WM 
by concurrently using cytoplasmic staining of the clonal cells. We also delineate the 
area of minimal deletion in WM, by using a set of 10 FISH probes located at 6q. 
Finally, we assess the prevalence of 6q- in IgM MGUS, an assumed precursor state 
of WM.
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Patients and methods
Patients
We studied 38 WM patients and 12 IgM MGUS who fulfilled the clinical diagnosis 
of WM or IgM MGUS 7,8 (Table 1). The study was conducted under the approval of 
Mayo Clinic Institutional Review Board and in accordance with the Declaration of 
Helsinki for research with human subjects. For this particular study, and to attain 
greater stringency in our diagnostic criteria, each WM patient was required to have a 
serum IgM paraprotein level of 1,500 mg/dL or greater and clonal lymphoplasmacytic 
infiltration comprising at least 20% of the mononuclear cells in the bone marrow 
(BM) biopsy. The BM involvement at diagnosis could be 10-19% if the patient’s 
monoclonal protein level exceeded 3,000 mg/dL. Patients were classified as having 
IgM MGUS according to standard criteria, namely 10% or fewer monotypic plasma 
cells (PCs) or lymphoplasmacytic cells in the BM biopsy and an IgM monoclonal 
serum protein concentration of 3,000 mg/dL or less, and no evidence of MM or WM. 
In seven IgM MGUS patients the BM sample was taken at the time of diagnosis.
Samples and FISH probes used
In the cases studied, BM aspirates were enriched for mononuclear cells using the 
Ficoll method and cytospin slides were made. For the FISH assays, we used our 
previously published techniques 2. Briefly, we used FISH combined with cytoplasmic 
immunoglobulin M (cIgM) staining with an AMCA (7-amino-4-methylcoumarin-3-
acetic acid)-conjugated anti-IgM antibody (cIgM-FISH). We also used cytomorphol-
ogy for the detection of the clonal cells on cytospin slides. A total of 10 probes were 
Table 1. Clinical characteristics IgM MGUS and WM patients.
IgM MGUS
(n = 12)
WM
6q present
(n = 17)
6q deleted
(n = 21)
WM Total
(n = 38)
Sex
 Male 6 (50%) 9 (53%) 14 (67%) 23 (61%)
 Female 6 (50%) 8 (47%) 7 (33%) 15 (39%)
Light chain type (%)
 κ 10/12 (83%) 11/17 (65%) 14/20 (70%) 25/37 (68%)
 λ 1/12 (8%) 6/17 (35%) 6/20 (30%) 12/37 (32%)
biclonal 2/12 (17%) 0/17 (0%) 3/20 (14%) 3/37 (8%)
B2-microglobulin > 3.5 mg/dL 0/9 (0%) 3/16 (19%) 6/17 (35%) 9/33 (27%)
Albumin < 3.5 g/dL 1/12 (8%) 7/17 (41%) 6/20 (30%) 13/37 (35%)
Hemoglobin < 11 g/dL 0/12 (0%) 4/16 (25%) 12/21 (57%) 16/37 (43%)
Serum IgM > 3,000 mg/dL 0/12 (0%) 11/15 (73%) 15/20 (75%) 26/35 (74%)
Serum IgM spike > 3.0 g/dL 0/9 (0%) 7/16 (44%) 7/20 (35%) 14/36 (39%)
Median % PC BM involvement (range) 5 (0-10) 20 (10-90) 50 (10-90) 30 (10-90)
6q deletion in macroglobulinemia and MGUS 53
used, including 2 commercially available probes (CEP 6 and Telomere 6q, Vysis Inc., 
Downers Grove, IL USA) and eight BAC or PAC clones (Invitrogen, Carlsbad, CA 
USA) developed in our laboratory. Clones were selected based on a specific gene 
encompassed in the insert and/or localization on the 6q arm and validated by PCR 
and normal metaphase slides. Genes of interest included BLIMP1 (RPCI-1 134E15, 
RPCI-1 101M23), MYB (RPCI-1 32B1), BTF/BCLAF1 (CTD 2600I3), SHPRH (RPCI-11 
164A17), LATS1 (RPCI-11 52G20) and FOP/FGFR1OP (RPCI-1 167A14). Finally, two 
probes localizing to 6q13 (RPCI-11 553A21) and 6q15 (RPCI-11 113K07) were ap-
plied. In IgM MGUS samples, only the probes encompassing genes BLIMP1, MYB 
and SHPRH were applied simultaneously with the CEP 6 probe.
Statistics and scoring criteria
The signal pattern of each sample was identified under an epifluorescence micro-
scope with fluorescein isothiocyanate, Texas red, and a DAPI filter. We attempted 
to score at least 100 clonal cells from each patient, but a sample was considered 
evaluable if at least 20 cells were scored. In the cytospin slides, only cells identified 
by morphologic features as lymphoplasmacytic were scored. Based on our previous 
FISH studies2,9, an abnormal pattern is determined if the percentage of cells exceeded 
the mean percentage background level plus 3 standard deviations found for normal 
cells. Therefore a cut-off of 10% or greater was used to indicate a patient sample 
with evidence of deletion for a probe studied. This cut-off was not critical because, 
in most cases, the deletions involved the majority of the clonal cells.
results
MGUS Patients
A total of 12 IgM MGUS patients were selected for this study (six women, six men; 
median age at diagnosis, 64 years). Two cases showed a pattern that was indicative 
of a biclonal (IgMκ/ IgGκ) B-cell involvement by protein electrophoresis and im-
munofixation, but IgM was the predominant protein. Five patients had IgM MGUS 
associated peripheral neuropathy, a common characteristic of IgM paraproteinemia10. 
One patient had received chlorambucil and prednisone as treatment for a painful pe-
ripheral neuropathy. Two patients had been successfully treated with plasmapheresis 
for their peripheral neuropathy, but no hyperviscosity symptoms were observed. One 
patient had received prednisone and azathioprine for ulcerative colitis treatment. 
The BM samples showed PCs in all but three cases (range; 0-10% involvement). 
Three BM samples contained a mixture of small lymphocytes and plasmacytoid cell 
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comprising 5, 9 and 10% of the BM, respectively. None of the IgM MGUS patients 
showed progression to WM or other malignant stage during follow up.
Waldenström macroglobulinemia patients
Thirty-eight WM were included (15 women, 23 men; median age at diagnosis, 67 
years). Three patients had histological proof of amyloid deposition. Seventeen 
patients had received no treatment for WM prior to their BM sample. The other 
patients had received prior treatment with alkylating agents, purine analogs, anti-
CD20 antibodies and/or corticosteroids. Cytogenetic results of this cohort of WM 
patients were successful in 14 cases (data not shown). Seven cases (50%) showed 
an abnormal karyotype but no 6q deletion was detected. Clinical parameters of IgM 
MGUS and WM patients are summarized in Table 1.
cIgM-FISH
In the 12 IgM MGUS cases studied, no abnormal pattern was detected by using two 
probes, encompassing BLIMP1 and MYB, simultaneously with CEP 6. In nine IgM 
MGUS cases we were also able to apply the probe covering gene SHPRH together 
with CEP 6. No abnormal pattern was scored. Based on these results we decided 
not to apply the other probes in IgM MGUS. In five cases previously performed 
FISH studies did not detect evidence of chromosome 14 translocation using the 
‘break-apart’ strategy (data not shown). As expected, 6q deletions were detected in 
21 WM cases (55%) using any of our probes on 6q (Figure 1). One WM case had a 
monosomy for chromosome 6 (case 21, Figure 1).
Area of minimal deletion in WM
To define the area of minimal deletion at chromosome 6q, 29 WM cases were suc-
cessfully studied by using all ten probes. In nine WM cases probe ‘coverage’ was not 
complete, either due to hybridization problems or lack of slides. In the 21 WM cases 
showing deletion of 6q, three had an interstitial deletion (cases 2, 3 and 13, Figure 1). 
probe location 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
CEP6 centromere
q13  6q13
q15  6q15 normal
BLIMP1  6q21-q22.1 abnormal
MYB  6q22-q23 no information
BTF  6q22-q23
SHPRH  6q24.3
LATS1  6q24-q25.1
FOP  6q27
TEL6q  telomere
WM cases
ch
ro
m
os
om
e 
6
p
q
11
12
13
21
15
16
22
23
24
14
25
26
27
 
Figure 1. FISH results in WM cases with 6q deletions.
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The remainder of these cases showed deletions of large segments, including the 
telomeric probe. The probe encompassing SHPRH (at 6q24) was the most frequently 
deleted of the ten probes. Because FISH cannot precisely define the outside margins 
of the deletion, we conclude that the likely boundaries of the “area of minimal 
deletion” are 6q23 and 6q24.3.
discussion
Although WM and IgM MGUS are considered closely related diseases, we dem-
onstrate in this study that 6q deletions are uncommon in IgM MGUS. Recent data 
showed that 6q deletion is uncommon in nodal LPL, which suggests that WM has 
a different cytogenetic and biologic profile compared to nodal LPL 11. We speculate 
that 6q- could serve as a specific genetic marker for WM.
Our data show that 6q deletions assessed by cIgM-FISH are the most common 
chromosomal abnormalities in WM, with a prevalence of 55%. Strikingly, although 
many WM cases display loss of almost the complete 6q arm as detected by cIgM-
FISH, conventional cytogenetics was not able to detect this abnormality in any of 
the cases. Therefore we suggest that the cIgM-FISH assay is a sensitive test to detect 
6q- in WM.
Deletions of 6q have been described in other hematological malignancies and 
solid tumors. In non-Hodgkin lymphomas (NHL) three distinct regions have been 
defined and associated with disease grade/sub-type: 6q21-23 in high grade NHL; 
6q25-27 in intermediate grade NHL, and 6q23 in low grade NHL. In this study we 
delineate the area of minimal deletion between 6q23 and 6q24.3. Several candidate 
tumor suppressor genes have been suggested for this area. The FISH probe SHPRH 
covering the SRPRH gene locus at 6q24, was deleted most frequently. The protein 
product (SHPRH) of this gene contains five functional domains (SNF2, histone linker, 
PHD, RING and helicase). It is speculated that SHPRH plays a role in chromatin-
mediated transcription and therefore is a candidate tumor suppressor gene. However, 
functional studies are required to elucidate its exact biological role12.
In WM the 6q deletion is probably a progression event most commonly observed 
in WM, but not in the pre-malignant phase of the disease. Our preliminary clinical 
observations suggest a correlation between 6q deletions and more aggressive clinical 
features. Other authors have associated deletions of 6q23 with a low-grade subset 
NHL, with small lymphocytic and plasmacytic morphology13.
The cell of origin in IgM MGUS is unknown. For IgG and IgA MGUS it has been 
well established that BM clonal cells harbor similar recurrent aberrations, compared 
to the malignant stages (multiple myeloma and related disorders). Therefore, BM is 
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most likely the location of the main clonal population. IgM MGUS will progress to a 
malignant stage in 17% of the cases. In the progression of IgM MGUS to lymphoma, 
it is likely that a lymph node harbors the cell of origin. In the progression of IgM 
MGUS to WM, primary amyloidosis and chronic lymphocytic leukemia, the BM is 
likely the residing place of the clonal cell. The unknown progression path hampers 
IgM MGUS studies based on BM tissue. Ideally, a study using paired samples from 
patients having progressed from IgM MGUS to WM would be more informative.
In conclusion, the prevalence of 6q- is 55% in WM and therefore the most common 
aberration. We have also shown that deletions at this region are uncommon in IgM 
MGUS. The probe for 6q24 could be used to distinguish WM from IgM MGUS, but 
more study is necessary to prove its utility as a clinical marker. Finally, we delineated 
an area of minimal deletion (6q23-24.3) in WM and speculate that this is a second-
ary event involving a tumor suppressor gene at this locus which results in a more 
aggressive subset of the disease.
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abstract
Fluorescence in situ hybridisation (FISH) is an effective technique for the cytoge-
netic analysis of Waldenström macroglobulinemia (WM) but the potential impact 
of molecular cytogenetics on disease evolution and as a prognostic marker is still 
unknown. Deletion of the long arm of chromosome 6 (6q-) is the most frequent 
cytogenetic abnormality in WM. This study analysed the prevalence of this aberra-
tion in 102 WM patients, and we have correlated it with disease characteristics. The 
incidence of 6q21 deletion was 7% by conventional cytogenetics and 34% when an-
alysed by FISH (54% when cytoplasmic immunoglobulin M-FISH was used). Patients 
with deletion of 6q displayed features of adverse prognosis such as higher levels 
of β2M and monoclonal paraprotein and a greater tendency to display anaemia and 
hypoalbuminemia. Interestingly, there was a correlation between the presence of 
6q deletion and the International Staging System prognostic index (incidence of 6q- 
among patients stratified in stages 1, 2 and 3 was 24%, 42% and 67% respectively). 
Those patients diagnosed with smouldering WM who displayed the abnormality 
showed a trend to an earlier requirement of treatment. Finally the survival analysis 
did not show differences between the two groups of patients, probably due to the 
short follow up of our series.
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introduction
Waldenström macroglobulinemia (WM) is a B-cell clonal disorder that affects elderly 
patients. The rarity of this disorder, as well as its location at a crossroads between 
chronic lymphoproliferative disorders, low grade lymphomas and monoclonal 
gammopathies, creates frequent controversies surrounding the WM pathogenesis. 
Immunophenotypic1,2, cytogenetic and molecular 3-5 studies have been carried out 
to gain insight into the characteristics of the malignant clone. Cytogenetic studies in 
WM have been hampered by the low mitotic index of the tumour cells. Thus, only 
five meaningful series of patients have reported on the karyotypic findings of WM, 
and included altogether 165 patients6-8. The frequency of cytogenetic abnormalities 
in these series was quite low (35%, range: 17%-37%) and the most recurrent change 
was 6q deletion with an occurrence of 6%-16%. Other less frequent abnormalities 
were the loss of 13q mostly seen in cases with advanced disease9, and trisomy of 
chromosome 5 and chromosome 8 but observed in less than 10% of patients.
To overcome the low yield of karyotype in low proliferative diseases alternative 
techniques such as fluorescence in situ hybridization (FISH) have been used for the 
study of the disease9-11. Deletions of the long arm of chromosome 6 are reported 
with a frequency of up to 63% 8 while some other aberrations, typical of related 
B-cell neoplasms such as loss of RB1 or immunoglobulin heavy chain (IgH) locus 
rearrangements, have been only rarely detected in WM patients (9%-16% 9,11 and 
3-14% 8,11 respectively). Because of the small number of patients studied, a compre-
hensive analysis in a large series of patients is warranted in order to better define the 
prevalence of chromosomal changes present in WM.
Although the clinical course is usually indolent, the disease may evolve in two 
patterns: around one third of the patients are asymptomatic at the time of diagnosis 
and do not require treatment but only observation. This group is also often referred 
to as ‘smouldering’ WM. The rest are symptomatic due to lymphoid infiltration (with 
consequent bone marrow insufficiency) and/or to the presence of immunoglobulin 
M (IgM) paraprotein (and the complications arising from it). Among this second 
group of patients, some display features of aggressive disease and have a shorter 
survival. While there are some prognostic models devised to estimate the prognosis 
of WM patients, these models are mostly based on host features (e.g. age, cytope-
nias, albumin, organomegaly),12-17 and not in intrinsic features of the clonal cells. 
Dimopoulos et al (2004) recently demonstrated that the International Staging System 
(ISS) for multiple myeloma (MM), by using albumin and β2-microglobulin (β2M) 
levels, could also be applied to WM. The different pathways for clinical behavior 
have stimulated investigation of new prognostic factors, particularly genetic ones 
that can better predict disease outcome. So far no studies have been carried out 
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that explore the potential impact of cytogenetics on WM disease evolution, despite 
genetic changes dictating clinical heterogeneity among many other hematological 
neoplasms, such as chronic lymphocytic leukemia (CLL) 18-21and MM22-26.
In the present study we have analysed the prevalence of 6q deletion in a relatively 
large number of patients with WM and we have correlated the results with the 
clinical and biological features of these patients.
Patients and methods
Patients and samples
Bone marrow samples from 102 patients diagnosed with WM from two different 
institutions were included in the study. Sixty-two of them had been studied at Mayo 
Clinic (USA) while the other 40 were from Salamanca (Spain). Diagnostic criteria 
used were those proposed at the consensus panel of the Second International Work-
shop on Waldenström’s Macroglobulinemia1: presence of IgM paraprotein in the 
serum and infiltration in the bone marrow trephine biopsy by lymphoplasmacytic 
lymphoma as defined by the presence of an infiltrate of lymphocytes, lymphoplas-
mocytes and plasma cells. Immunohistochemistry was also performed in some of the 
cases, showing in all of them light chain restriction, presence of pan-B antigens such 
as CD79a and CD20 and expression of CD38 in the plasma cell population. Other 
B cell lymphoprolipherative disorders were excluded by the lack of expression of 
CD5, CD10 and CD23. In those cases in which a trephine biopsy was not available 
a lymphoplasmacytic involvement of at least 20% in bone marrow aspirate was 
required. The clinical features of this cohort of patients are summarized in Table 1. 
Thirty patients (29%) were diagnosed with smouldering WM. This diagnosis required 
the absence of any symptom attributed to the tumour burden or to the paraprotein 
and at least 12 months without treatment after diagnosis. Most of the patients were 
studied at diagnosis, while 35% of them had received treatment previously to the 
cytogenetic analysis. The median follow-up of the patients included in the analysis 
was 36 months.
Patients were stratified according to the ISS in three categories: Stage I: albumin 
≥ 35 g/L and β2M < 35 mg/L; stage II: albumin < 35 g/L and β2M < 35 mg/L or β2M 
35-55 mg/l and stage III: β2M > 55 mg/l.
Conventional cytogenetics
Bone marrow cells were cultured in RPMI medium supplemented with 15% fetal 
calf serum, penicillin and L-glutamine. All samples were cultured for 72 h with 
TPA (12-O-tetradecanoylphorbol 13-acetate) as previously described. At least 20 
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metaphases were necessary to consider a case evaluable for analysis. Chromosomes 
were identified by G-banding and karyotypes were described according to the 
International System for Human Cytogenetics Nomenclature (ISCN, 1995)27. Conven-
tional karyotype studies were available in 55 patients (27 from Mayo Clinic and 28 
from Spain).
Fluorescence in situ hybridization
In 98 WM patients, deletions of 6q were assessed by either simple interphase FISH 
performed on cell nuclei (n = 63, Salamanca and Mayo Clinic) or cytoplasmic IgM 
(cIgM)-enhanced FISH (n = 39, Mayo Clinic) according to our previously published 
techniques28,29. The principal aim of the present study was to analyze the prognostic 
implications of deletion of 6q in WM patients, so, although a number of different 
probes were used, we only strived to ascertain in a qualitative manner whether dele-
tions of chromosome 6 were present or not. In 29 of these patients, 6q21 deletion 
Table 1. Clinical and laboratory characteristics of the 102 patients included in the study.
Parameter % of patients
age (years)* 68 (44-94)
sex
Male 65%
Female 35%
light chain
Kappa 76%
Lambda 24%
Previous treatment
Yes 35%
No 65%
Wm
Symptomatic 71%
Asymptomatic 29%
igm (mg/l)
> 20 79%
< 20 21%
bm lymphoid infiltration (%)
> 40 36%
< 40 64%
hemoglobin (g/l)
> 110 50%
< 110 50%
albumin (g/l)
> 40 32%
< 40 68%
β2m (mg/l)
> 40 29%
< 40 71%
crP (mg/l)
> 35 25%
< 35 75%
esr (mm/h)
> 100 56%
< 100 44%
iss
1 45%
2 41%
3 14%
* Continuous variable: results given as median (range)
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was screened using a probe derived from clone RP11 91C23 (obtained from Oakland 
Children’s Hospital, Oakland, CA) with simultaneous hybridization of a centromeric 
probe for chromosome 6 CEP 6 (Vysis, Downers Grove IL)8. In the other 73 patients, 
two probes, derived from clones RP1-134E15 and RP1-32B1 (Oakland Children’s 
Hospital, Oakland, CA) that include genes BLIMP-1 and MYB, were hybridized 
simultaneously with CEP 6.
A minimum of 100 cells were analysed in all patient samples using Vysis scoring 
criteria. The cut-off point for the identification of alteration was set at ≥10% cells 
with abnormal signal
Statistical analysis
The Chi-square and the Mann-Whitney U-tests were used to estimate the statistical 
significance of differences between groups. A P-value <0.05 was used to define 
statistical significance. Survival analysis was performed using Kaplan-Meier method 
and the statistical significance inter-groups was evaluated with the log-rank test. 
The statistical analyses were carried out using the Statistical Package for the Social 
Scienses (SPSS) software-11.0 version (SPSS Inc. Chicago, IL, USA).
results
Conventional cytogenetics
Abnormal metaphases were present in 22 (40%) of the 55 patients that had metaphase 
cytogenetics information available, probably selecting a bias of the ordering physi-
cians, secondary to perceived clinical need. Four cases presented with 6q deletion 
(7%). Abnormalities in chromosome 14 were observed in five patients 30, with +14 
in four cases and add(14)(q32) in the remaining case. Other recurrent abnormalities 
were del(11)(q21), an additional chromosome 5 and monosomy of chromosomes 8 
and 18. Three patients displayed a hyperdiploid karyotype.
FISH
Of the 102 patients included in the study, deletion in the 6q21 region was present 
in 40 of them 30. Obviously, due to the different sensitivity of both techniques, the 
percentage of cases with 6q deletion was higher in patients analyzed by cIgM-FISH 
(54%) than in cases studied by conventional FISH (30%). Given our desire to only 
ascertain in a qualitative fashion for the presence of 6q deletions, and to increase 
our sample size for the clinical correlations we decide to include all patients tested, 
whether studied by cIgM-FISH or not. Only in four of these 39 patients with 6q 
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deletion detected by FISH was the abnormality also detected by conventional cyto-
genetics.
In 73 patients, two different probes localised at 6q21 were investigated: one con-
taining BLIMP-1 and one containing MYB. In 30 out of the 31 patients with deletion 
who were analysed with these two probes, the MYB signal was lost. By contrast, 
the signal for BLIMP-1 which represents the most centromeric region of 6q21, was 
deleted in only 26 cases. CEP 6 was lost in only one of the patients analysed, indicat-
ing that the existence of monosomy in these cases is uncommon.
Correlation between molecular cytogenetic changes and disease characteristics
Upon comparing the FISH results with the clinical characteristics of patients, we ob-
served that cases with 6q deletion displayed features which, in previous studies, have 
been associated with worse prognosis in WM (Table 2). Patients with 6q- presented 
significantly with higher levels of β2M (β2M ≥ 40 mg/L: 52% vs. 14%, P=0.001), 
anaemia (Hb < 11o g/L in 66% vs. 40%, P=0.01) and hypoalbuminemia (albumin < 
4o g/L in 90% vs. 54% of cases respectively P=0.001). The amount of paraprotein 
has also been described in some reports as having prognostic influence in WM, 
and, in the present series, IgM levels were higher than 20 g/l in 90% of patients 
with loss of 6q as compared with 72% of patients without the deletion (P=0.03). In 
contrast, age showed no difference between both groups of patients (69±8 vs. 66±11, 
P=0.26). Patients with the cytogenetic aberration also displayed more frequently 
elevated rates of acute phase reactants, such as erythrocyte sedimentation rate 31 and 
Table 2. Clinical and biological features of WM patients with and without deletion of 6q.
6q- (n=40) Non 6q- (n=62) p
β2m > 40 mg/l 52% 14% 0.001
albumin < 40 g/l 90% 54% 0.001
crP > 35 mg/l 47% 12% 0.006
hb < 110 g/l 66% 40% 0.01
igm > 20 g/l 90% 72% 0.03
esr > 100 mm/h 73% 46% 0.04
iss
1 29% 55%
0.052 46% 37%
3 25% 8%
requirement of treatment 87% 67% 0.02
age (years) 69 ± 8 66 ± 11 0.26
Wm symptomatic 75% 68% 0.28
sex male 70% 62% 0.28
bm infiltration >40% 40% 33% 0.381
Previously treated 41% 32% 0.27
time from diagnosis to test (months)* 35.6 (53.2) 29.4 (44.7) 0.61
* Continuous variable: results given as mean (standard deviation)
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C-reactive protein (CRP). There was no difference in the prevalence of 6q deletion 
between patients with symptomatic and indolent WM (42% vs 33%, P=0.28).
We also analysed if there was any correlation between the deletion of 6q and the 
ISS prognostic index. And we observed that, with differences close to the limit of 
significance, the frequency of 6q- increased with the stage of the ISS. In this sense, 
only 24% of patients in stage 1 displayed the abnormality as compared to 42% and 
67% in patients included in stage 2 and 3 respectively (P=0.05).
No differences were observed in the frequency of 6q deletion among those cases 
analysed at the moment of diagnosis and those who had been previously treated 
(35% vs. 44% respectively, P=0.27). Similarly, 6q- was not correlated with the time 
spent from diagnosis to the cytogenetic analysis, as it was 35.6 months for patients 
with the deletion as compared with 29.4 months for those without the abnormality 
(P=0.61).
Prognostic impact of molecular cytogenetic changes in WM
Regarding the prognosis, patients that had deletion of 6q frequently required treat-
ment; 87% of patients with 6q- required treatment while only 67% of patients without 
the abnormality were treated during the evolution of their disease (P=0.02). We 
further investigated the importance of loss of 6q in the timing of treatment among 
those cases diagnosed with smouldering disease who, for this reason, were not 
treated at the moment of diagnosis. And in this subset of patients, those with 6q 
deletion displayed a shorter treatment free survival (median of 55.2 months), when 
compared to not reached after a follow-up of 100 months for patients without the 
deletion (P=0.03) (Figure 1).
The survival analysis did not reveal a clear association with 6q deletion in the 
global subset of patients. When only those patients with symptomatic WM were 
analysed, the survival curve of patients displaying the abnormality was slightly worse 
than that of patients without the abnormality, although differences were not statisti-
cally significant (Figure 2).
discussion
Information on cytogenetic abnormalities in WM is scarce due to the low proliferative 
index of the tumour cell population and the rarity of the disease. As a consequence, 
studies that seek to correlate the cytogenetic profile and clinical outcome of WM 
patients are, by their nature, complex and may require the use of aggregate data 
from multiple institutions.
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Figure 2. Overall survival for patients with symptomatic WM. Patients with 6q deletion (n=30) did not displayed an statistically 
significant poorer survival than those without 6q deletion (n=39).
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 Figure 1. Treatment free survival for patients with smouldering WM. Patients with 6q deletion (n=10) required treatment 
sooner than those without 6q deletion (n=18).
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By necessity, the present study combined the patients of two institutions. All pa-
tients were analyzed by FISH. In one-third of cases, tumour population was detected 
and scored by use of additional cIgM staining (cIgM FISH). Although the sensitivities 
of the two techniques may differed slightly, we believe that the overall sensitivity is 
sufficient on a population scale to assess the role of 6q status in WM.
In the present series, by performing conventional cytogenetics (CC) and FISH 
analysis targeting 6q region, up to 55% of WM patients displayed cytogenetic aberra-
tions. Previous reports have shown that 6q- is the most common abnormality, either 
by conventional cytogenetics6-8 or FISH8,32, up to the point that it has become a WM-
associated marker6,7,33. The prevalence of 6q deletion by means of FISH was 39% in 
our series, although we could find some differences among those patients analysed 
by cIgM-FISH and those analysed with conventional FISH, because of the different 
sensitivity of both techniques. In this sense, 54% of patients analysed by cIgM-FISH 
displayed the abnormality when compared with only 30% among those patients an-
alysed by interphase FISH. Nevertheless, even when employing the less sensitive of 
these techniques, 6q deletion was the most frequent abnormality of all those tested 
in WM. Although this abnormality is also observed in other B-cell neoplasms, it is 
usually present at a much lower frequency34-36. In addition, a detailed mapping study 
has shown that 6q deletions are large deletions and clonally selected, and that is 
present in the majority of clonal plasma cells (R. Fonseca, personal communication). 
Because of its recurrent nature it has been suspected that the chromosome 6q region 
harbours a tumour suppressor gene of pathogenetic significance for WM8,36. The 
precise timing of deletions as a mechanism of loss of heterozygosity is unknown 
(i.e. at disease initiation versus as a progression event). Limited information sug-
gests the latter, given that 6q deletions appear to be uncommon in IgM monoclonal 
gammopathy of undetermined significance (MGUS), a precursor state of WM. Our 
study showed no difference in the frequency of 6q deletion at diagnosis compared 
to previously treated patients. The time spent from diagnosis to performance of FISH 
analysis was similar in both groups.
When we stratified WM patients according to 6q deletion, we observed that, in line 
with our previous observations in a smaller group, 6q- patients were more likely to 
display laboratory features associated with adverse prognosis14-17, such as high levels 
of β2M and paraproteinemia, or hypoalbuminemia. The ISS, a recently proposed 
prognostic index for WM, showed a trend (P=0.05) to display more frequently 6q- 
in those cases with advanced stages of the disease. Other differentiating markers 
were some acute phase reactants, like CRP or ESR, which displayed higher levels in 
cases with the deletion. The similar incidence of 6q deletion in asymptomatic and 
symptomatic WM, despite its tendency to display adverse prognosis, is intriguing. 
Nevertheless a parallel situation has been observed for 13q deletion and t(4;14) in 
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MM; while these cytogenetic abnormalities have been associated with worse outcome 
in MM26,37, their incidence is similar in both MGUS and symptomatic MM38.
This correlation of the presence of 6q deletion with clinical and biological pa-
rameters of advance disease was also confirmed by the fact that these patients also 
had a higher requirement of chemotherapy treatment. In fact, the great majority 
of patients (87%) with loss of 6q were treated during the evolution of the disease, 
while one-third of the patients without loss of 6q never required treatment in our 
series (P=0.02). This data, combined with the shorter time to receive treatment for 
patients diagnosed with indolent WM who have 6q deletion, suggest that patients 
with the deletion who are asymptomatic or with mild symptoms at diagnosis should 
be carefully followed because most of them will progress to a clear symptomatic 
form and treatment should be started as soon as possible.
In our opinion, the lack of impact of 6q deletion in the survival analysis can be 
explained by the short follow-up of the patients included in the study. The indolent 
nature of WM and the long survival these patients are well known, and makes it 
necessary to follow the patients for a long time to be able to show differences in 
survival. In our relatively large study, although some of the patients have a very long 
follow-up (longer than 10 years), half of them were diagnosed in the last 3 years 
(median follow-up 36 months), and therefore, a longer follow-up of these groups of 
patients could reveal greater differences in their outcome.
In summary, our results show that cytogenetic abnormalities in WM may contribute 
to a greater understanding of the disease heterogeneity and could help to identify 
patients in different prognostic groups.
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abstract
Waldenström macroglobulinemia (WM) is a B-cell malignancy characterized by the 
ability of the B-cell clone to differentiate into plasma cells. Although the clinical syn-
drome and the pathological characteristics are well defined, little is known about its 
biology and controversy still exists regarding its cell of origin. In this gene-expression 
study, we compared the transcription profiles of WM with those of other malignant 
B cells including (chronic lymphocytic leukemia [CLL] and multiple myeloma [MM]) 
as well as normal cells (peripheral blood B-cells and bone marrow plasma cells). 
We found that WM has a homogenous gene-expression regardless of 6q deletion 
status and clusters with CLL and normal B-cells on unsupervised clustering with very 
similar expression profiles. Only a small gene set has expression profiles unique to 
WM compared to CLL and MM. The most significantly up-regulated gene is IL6 and 
the most significantly associated pathway for this set of genes is MAPK signaling. 
Thus, IL6 and its downstream signaling may be of biologic importance in WM. Fur-
ther elucidation of the role of IL-6 in WM is warranted as this may offer a potential 
therapeutic avenue.
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introduction
Waldenström macroglobulinemia (WM) is a clinico-pathologically distinct B-cell ma-
lignancy characterized by intramedullary monoclonal expansion of predominantly 
small B-lymphocytes with variable plasmacytoid differentiation in the bone marrow 
(BM), associated with serum IgM paraprotein. Histologically, this represents bone 
marrow involvement by lymphoplasmacytic lymphoma 1.
Although the clinical disease spectrum has been well established, little is known 
about its biology. The cell of origin is thought to be an unusual memory B-cell that 
has undergone somatic hypermutation in the absence of antigenic selection with 
failure in the class switch recombination 2,3. Genetically, unlike many other B-cell 
malignancies, translocations involving the IgH locus on chromosome 14q32 are rare 
in WM 4,5. Karyotypic analysis is hampered by a low yield of abnormal metaphases. 
The most common genetic abnormality is deletion of the long arm of chromosome 
6 5,6. However, this cytogenetic abnormality is not unique to WM and its biological 
and clinical significance in WM has yet to be elucidated.
In this study, we undertook a gene-expression profiling (GEP) study of WM using 
CD138+ and CD19+ selected malignant bone marrow cells, and compared their tran-
scription program with related B-cell malignancies chronic lymphocytic leukemia 
(CLL) and multiple myeloma (MM) as well as normal B-cell and plasma cell (PC) 
counterparts. The selection of cells using both CD138 and CD19 should encompass 
the full spectrum of malignant cells, so that we can define a molecular signature 
for WM, its relation to other normal and malignant B-cell counterparts, and identify 
biologically relevant and important pathways, new disease markers and potential 
therapeutic targets in an unbiased fashion. We found that the transcription profile of 
WM is very similar to CLL and normal B-cells, and distinct from MM and normal PCs. 
Only a small gene set is unique to WM. Pathway analysis of genes unique to WM 
provide further insights into the biology of this disease.
materials and methods
Samples
Twenty-three WM, 8 CLL, 101 MM, 24 SMM, 22 monoclonal gammopathy of un-
known significance (MGUS; including 1 IgM MGUS), 15 normal PC and 7 normal 
B cells were included in this study. Blood and BM samples were procured after 
informed consent was obtained in accordance with the Declaration of Helsinki. 
The study was approved by the Institutional Review Board of the Mayo Clinic. The 
samples were enriched for cell population of interest using immunomagnetic beads 
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(AutoMACS, Miltenyi-Biotec, Auburn, CA). For WM and the case of IgM MGUS, 
CD19+ and CD138+ (concurrent but not sequential) selected BM cells were used. For 
MM, SMM, MGUS and normal PCs, CD138+ selected BM cells were used. For CLL and 
normal B cells, CD19+ selected peripheral blood cells were used. The CLL, WM and 
PC neoplasm samples were consecutive samples with quantitatively and qualitatively 
adequate RNA for gene-expression study. The common cytogenetic abnormalities 
and categories were present (6q deletion for WM, IgH translocations, 13 deletion and 
hyperdiploidy for MM, and mutated and unmutated IgVH for CLL) in these patients 
at frequencies similar to published data (data not shown).
Gene-expression profiling
RNA was extracted from the enriched cells. Gene-expression analysis was performed 
using the Affymetrix U133A chip for WM, MM, SMM, MGUS and normal PCs and 
the U133A and U133B chips for CLL and normal B cells (Affymetrix, Santa Clara, 
CA). RNA isolation, purification and microarray hybridization have been previously 
reported 7. Gene-expression intensity values were log transformed, normalized to the 
median and analyzed using GeneSpring 7 (Agilent Technologies, Palo Alto, CA).
Gene-expression analysis
For all analysis, the universal gene list was all genes on the U133A chip minus immu-
noglobulin genes (total 22104 genes). To define the relation between WM, CLL, PC 
neoplasm, normal PCs, and B-cells, we first generated a list of genes whose expres-
sion varied significantly across individual samples by Welch ANOVA using variance 
computed by applying the Cross-Gene Error Model (CGEM) based on Deviation from 
1 available within GeneSpring. This overcomes the lack of replicates and variance 
associated with the individual samples and is similar in principle to variance filtering. 
The generated gene list was then used for unsupervised clustering of the CLL, WM, 
PC neoplasm, normal PCs and B-cell samples using a hierarchical agglomerative 
algorithm. To detect possible heterogeneity and identify subtypes within WM, all 
genes were used for unsupervised clustering. The Pearson correlation coefficient and 
centroid linkage were used as similarity and linkage methods, respectively.
To identify genes with unique gene-expression profiles for WM, CLL and MM, we 
first, identify genes with significantly different expression between WM, MM and 
CLL by ANOVA with Benjamini and Hochberg multiple testing corrections. Genes 
whose P value is less than .05 and that pass a false discovery rate (FDR) of 5% were 
selected for further filtering by fold change (2-fold or higher different expression 
between WM and others).A similar sequence was applied to MM and CLL. Finally, 
a Venn diagram incorporating the 3 filtered gene sets (1 each for WM, MM and 
CLL) was used to identify genes unique to each disease. The specificity of the WM 
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signature was further validated by leave-one-out cross-validation (LOOCV) using 2 
algorithms: the k-nearest neighbor (KNN) and the support vector machines (SVMs). 
In the KNN method, a sample is classified based on a majority vote of the classes 
of the k neighbor that are closest to it in terms of Euclidean distance. In the SVM 
method, a sample is classified based on its position relative to an optimal linear 
decision boundary constructed on a transformed feature space of the microarray 
data. For both methods, the predictor genes are those with unique profiles in WM 
compared to CLL or MM (significant by ANOVA after multiple testing corrections 
and greater than 2-fold difference in expression) as outlined. For the KNN method, 
optimal settings are number of neighbors of 15 and P value ratio of 0.1. For SVM, 
radial kernal function was used.
Inspection of some of these disease-specific gene lists revealed genes that could 
represent contaminating cell populations acquired during selection; pre-B cells (ex-
pressing NPTT [tdt], MME [CD10], VPREB1), and monocyte/macrophages (expressing 
CD36, CD163, CD14, APOE). Subsequently, we generated lists of genes whose ex-
pression may be the results of these contaminating cell populations by finding genes 
whose expression profiles were correlated with tdt (for Pre-B cells) and CD36 (for 
monocytes) using a Pearson’s correlation coefficient of 0.7 as the cutoff value.
Because the initial unsupervised clustering of samples may be affected by the pres-
ence of these contaminating cells, we extracted previously published CLL signature 
(unique to CLL when compared to different B cell types and B cell malignancies 
although not including WM or MM) 8. Unique MM signature has not been previously 
defined. As a compromise we extracted genes differentially expressed between MM 
and normal PCs previously published 9 as a surrogate for a MM signature. Interest-
ingly, the 2 gene sets do not overlap. Using both gene signatures, we clustered WM 
with CLL and MM samples to confirm the similarity between WM and CLL but not 
MM
Gene ontology and pathway / network analysis was performed using a web-based 
software, MetaCore (GeneGo Inc, St Joseph, MI). The software contains an interac-
tive, manually annotated database derived from literature publications on proteins 
and small molecules that allows for representation of biological functionality and 
integration of functional, molecular, or clinical information. Several algorithms to 
enable both the construction and analysis of gene networks were integrated as previ-
ously described 10. The output P values reflect scoring, prioritization and statistical 
significance of networks according to the relevance of input data.
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results
Gene-expression profile of WM is related to CLL and normal B-Cells
On unsupervised clustering, WM clustered together with normal B cells and CLL 
samples (first branching of the dendogram, Figure 1a). Furthermore, inspection of 
the heatmap suggested very similar profiles between these conditions. Of interest, 
the one case of IgM MGUS in the dataset clustered with WM instead of MGUS 
or normal PCs. WM samples were split into 2 groups with CLL and IgM MGUS 
clustered in between. The separation of WM into 2 clusters had no relation to 6q 
deletion status as both clusters had similar number of patients with 6q deletion 
(Supplementary Figure 1)11. The expression profile of the smaller WM cluster (which 
 
Figure 1. Gene-expression profile of WM is closer to CLL than MM. (a) Using 2162 gene probes that are variably expressed 
across the WM, CLL and MM samples, unsupervised clustering of these samples together with normal B-cells, PCs, MGUS 
and SMM was performed. Selected genes that clustered together and were overexpressed in different sample clusters are 
highlighted. Restricting our analysis to only WM, CLL and MM samples, unsupervised clustering was performed using published 
b) CLL and c) MM signatures. WM samples clustered predominantly with CLL samples and also exhibited closer approximation 
of gene-expression profile using both signatures to CLL. Some genes of interests are highlighted. In both heatmap, the colored 
bar at the bottom indicates the tumor type: blue = CLL, yellow = WM and red = MM. The scale of the gene-expression data is 
similar to figure 1a.
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clustered with IgM MGUS, WM cluster 1) was closer to normal B-cells than the larger 
WM cluster (WM cluster 2; Figure 1a). In addition, 2 WM samples clustered next to 
normal PCs and 1 sample clustered with MM and MGUS (WM cluster 3). In general, 
the percentage of plasma cells in the bead purified cells used for gene-expression 
profile increased from WM cluster 1 to WM cluster 3, suggesting the clustering of WM 
into these groups may reflect a difference in degree of plasmacytic differentiation of 
the tumor cells (Table 1).
Normal PCs and most of the MGUS samples clustered together. A significant num-
ber of genes overexpressed by these samples are genes expressed in monocytes/
macrophages (CD163, CD36, CD14, APOE, VCAM1). These genes were also overex-
pressed in some WM cases (Figure 1a). This probably represents genes expressed by 
contaminating monocytes/macrophages resulting from immunomagnetic bead selec-
tion of BM cells. This could be due to non-specific binding of beads to Fc receptors 
present on the surface of monocytes/macrophages or phagocytosis of these beads by 
the monocytes/macrophages. This was most apparent when the percentage of cells 
Table 1. Percentage of Plasma Cells and Bone Marrow involvement by tumor in WM samples and their correlation with 
contamination signature and clustering.
Samples PCs in purified samples 
(%)
BM involvement (%) Contamination 
Signature
Clustering
WM8 25 20-30 Nil WM 1
WM15 16 50-60 Nil WM 1
WM22 NA 60-70 Nil WM 1
WM25 8 80 Nil WM 1
WM2 45 10 Monocytes WM 1
WM10 26 80-90 Nil WM 1
WM24 70 10-20 Nil WM 2
WM17 38 80 Nil WM 2
WM3 18 30 Monocytes WM 2
WM12 26 20 Nil WM 2
WM5 90 60-70 Nil WM 2
WM19 NA NA Nil WM 2
WM20 NA NA Monocytes WM 2
WM11 28 30 Monocytes WM 2
WM4 36 20-25 Pre-B WM 2
WM18 NA NA Pre-B WM 2
WM7 NA 30 Pre-B WM 2
WM13 23 20 Pre-B WM 2
WM16 14 20-30 Pre-B WM 2
WM9 22 10 Pre-B WM 2
WM23 95 30 Monocytes WM 3
WM26 94 10 Monocytes WM 3
WM14 49 <5 Monocytes WM 3
Abbreviation: NA = Not available
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selected for was low in the bone marrow (in this case CD138+ PCs in normal and 
MGUS BM or WM samples with fewer malignant cells). This problem is less apparent 
if the tissue source of selection is peripheral blood (normal B cells and CLL samples) 
because monocytes are very minor populations of peripheral-blood cells. As cor-
roborating evidence, the WM cases with this monocyte contamination signature had 
the lowest degree of BM tumor involvement (Table 1). In view of the possible impact 
of these contaminating cells and their gene-expression on interpretation of results, 
we created list of genes that are highly correlated with these pre-B cell and mono-
cytes/macrophage genes, so that they can be subtracted from subsequent analysis of 
genes with expression profiles unique to the individual tumor types. There were also 
cases of MGUS that clustered with MM samples (Figure 1a). This is consistent with 
the well-known similarity in global gene-expression between MGUS and MM 9.
 
Figure 2. Contributions of genes from contaminating cell populations. (a) Closer inspection of some of the genes within the 
gene cluster overexpressed in normal B-cell, CLL and WM revealed some interesting differences. In particular, the concurrent 
overexpression of NPTT (tdt), MME (CD10), and VPREB1 in the WM samples suggested likely contamination with pre-B cells. In 
addition, ZAP70 and CCNB1 (as a representative gene from the proliferation cluster overexpressed in a subset of WM patients) 
overexpression is tightly associated with samples overexpressing NPTT (tdt), MME (CD10), and VPREB1. (b) To verify that tdt 
expression was originating from contaminating pre-B cells, immunostaining for tdt was performed on bone marrow biopsies 
from WM patients with and without the pre-B cell contamination signature. This figure is representative for samples with the 
contamination signature. Malignant cells (CD20 positive) formed intra-medullary clusters (marked by arrows; top panel H+E 
staining; middle panel CD20 staining). In contrast, nuclear tdt staining was seen in scattered interstitial cells that represented 
pre-B cells (right panel). In samples without the contamination signature, no tdt positive cells were seen. All images were at 40x 
magnification. The microscope used is a Zeiss Axioskop (Carl Zeiss Microimaging Inc, Thornwood, NY). Images were captured by 
the Olympus DP70 CCD camera using the DP controller image capture software (Olympus, Center Valley, PA).
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The 2-dimensional clustering also revealed different clusters of genes that were 
overexpressed in the different tumor/tissue types. The expression profiles of nor-
mal B cells, WM and CLL samples were very similar (Figure 1a). These samples 
overexpressed a cluster of genes that included B-cell markers such as CD22, CD19, 
CD79b, and CD11b, potential therapeutic targets such as CD52, prognostic markers 
(ZAP70), a set of genes normally expressed in pre-B cells (MME [CD10], VPREB1, 
NPTT [tdt]) and genes of potential biological relevance (IL6) (For a full list of genes in 
this cluster refer to supplementary material)11. The appropriate expression of B-cell 
markers provided some internal validation to the gene-expression data. We decided 
to look closer at the expression of IL6, ZAP70, MME, VPREB1 and NPTT in CLL 
and WM (Figure 2a). IL6 expression was high (>2-fold higher than CLL and MM) 
in most WM compared to CLL and normal B-cells. ZAP70 expression was high in 7 
of the 8 CLL samples and a subset of WM patients. MME, VPREB1 and NPTT were 
overexpressed in the same WM samples and most likely represent contaminating 
bone marrow pre-B cells resulting from the CD19 selection process. Interestingly, 
the expression of ZAP70 in WM was highest in the samples with the presumed pre-B 
cell contamination. In view of previous studies showing ZAP70 expression in normal 
B-cells 12,13 and lack of ZAP70 expression in WM 14, the ZAP70 expression in the 
subset of WM was most likely because of the contaminating pre-B cells.
A subset of WM appeared to overexpressed genes involved in cell cycle and 
proliferation (MAD2L1, CCNB1, CCNB2, TOP2A, NEK2, CENPE, CDC2). Interestingly 
these corresponded to the WM samples with the highest expression of ZAP70 but 
they did not constitute all the samples with the contaminating ‘pre-B cell signature’ 
(Figure 1a and 2a). As ZAP-70 is overexpressed in “activated” B cells 12, it is possible 
that these samples are contaminated with more activated and proliferating pre-B 
cells as compared to other WM samples.
To validate that these genes were expressed by contaminating cells, staining for 
tdt by immunohistochemistry was performed by an expert hemato-pathologist for 
5 samples with the contamination signature and 5 without and showed that tdt was 
positive only in the non-malignant pre-B cells (hematogones) in the 5 samples with 
the contamination signature and tdt staining was absent in the 5 samples without 
the contamination signature. A representative example is shown in figure 2b. This 
strongly suggested that overexpression of tdt and the strongly correlated set of pro-
liferation genes including ZAP-70 was due to the presence of contaminating pre-B 
cells.
Because our unsupervised clustering may be affected by these contaminating cells, 
we sought to verify the observation that the expression profile of WM was similar to 
CLL but different from MM by using published CLL and MM signature (see “Material 
and methods”). It was clear that using either signature, WM was clustered together 
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with CLL and not MM. Furthermore, the expression profile of genes constituting the 
2 signatures was more similar between WM and CLL than MM (Figure 1b-c).
WM has a homogeneous gene-expression profile.
Initial attempts to identify genes with variable expression across the 23 WM samples 
using ANOVA yielded a very small list of genes (<50). Therefore, we performed 
unsupervised clustering of WM samples using all genes. This analysis suggested a 
relatively homogeneous expression profile amongst the WM samples except for 4 
samples which underexpressed a subset of genes (Supplementary Figure 1)11. On 
closer inspection, these cases had the highest PC percentage and low BM involve-
ment, and the under-expression of these genes were also seen in normal PCs and 
MGUS but not in CLL or B cells (data not shown). These 4 cases were not IgM 
myeloma as the patients had no bone disease and were negative for t(11;14) 15, 
instead, they had lymphadenopathy or splenomegaly and in 1 case also a 6q deletion 
by in situ hybridization (FISH), which were all hallmarks of WM. There were no 
obvious difference in the expression profiles between samples with the 6q and those 
without the deletion because they clustered together on unsupervised clustering and 
no genes were differentially expressed between 6q-deleted and non-deleted cases.
Analysis of expression of cluster of differentiation (CD) markers, and genes involve in cell cycle regulation
In an attempt to identify possible diagnostic markers, we next analyzed the expres-
sion of cluster of differentiation (CD) markers among the samples. The expression 
of CD markers in WM was similar to CLL and B-cells and different from MM and 
normal PCs (Supplementary Figure 2a)11. The expression of B-cell markers such as 
CD19, CD20, CD22, CD23 and the common leukocyte antigen (CD45) in normal 
B-cells, CLL and WM but not MM; expression of CD5 in CLL but not normal B-cells, 
WM, MM or normal PCs; expression of PC markers such as CD38 and CD138 in MM 
and normal PCs but not in normal B-cells, CLL or WM provided internal validation 
of the gene-expression results as these were known immunophenotypic markers for 
the respective cell types (Supplementary Figure 2b)11. The low but higher expression 
of CD45 and CD19 in normal PCs compared to MM and expression of CD56 in MM 
but not normal PCs are consistent with the difference in the expression of these 
markers between normal and malignant plasma cells 16,17. In terms of potential new 
disease markers, CD1C was highly expressed in almost all cases of WM but was not 
expressed in CLL or MM; however strong expression was also seen in normal B-cells 
(Figure 2a and supplementary Figure 2b)11. CD200 was strongly expressed in CLL 
but not in WM or MM and expression was weaker in normal B-cells. Of therapeutic 
interest, CD52 was expressed in CLL and WM but not MM whereas CD117 (c-kit) 
was expressed in MM but not WM or CLL. CD20 appears to be expressed strongly in 
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normal B cells, CLL, WM with weak expression in MM (supplementary Figure 2b)11. 
Consistent with published data 18, the expression of CD20 was found predominantly 
in patients with t(11;14).
Because deregulation of the cell cycle is common in B-cell malignancies and 
these deregulated pathways are potential therapeutic targets 19, we investigated and 
compared the gene-expression of genes involved in these processes between CLL, 
WM and MM (supplementary Figure 2)11. The expression of cell-cycle genes was 
very similar between CLL and normal B-cells, whereas there were more differences 
between MM and normal PCs. WM seemed to have an intermediate pattern of ex-
pression for these genes. In terms of the D-type cyclins, CLL and WM only expressed 
CCND3 whereas MM expressed all 3 cyclin D genes. Of note, the CDKI genes were 
predominantly up-regulated in the malignant conditions compared to their normal 
cellular counterpart. In MM, p14, p15, p18 and p21 were up-regulated and only p27 
and p57 were down-regulated compared to normal PCs. In WM, p15, p18, and p57 
were up-regulated compared to normal B-cells (Supplementary Figure 3)11. This 
suggests that on the whole, CDKIs are up-regulated in these B-cell malignancies 
and we speculate that these are secondary responses to check proliferation of tumor 
cells. The expression of CCNB1 and CDC2 is usually an indication of proliferation. 
These were not expressed in CLL consistent with its known low proliferative index. 
The expression of these genes was significantly higher in WM and correlated with 
expression of DNTT, probably representing pre-B-cell contamination (Figure 2a).
Genes with distinct expression profile in WM, CLL and MM are involved in different pathways relevant to 
their biology
Seventy-three genes had a distinct expression profile in WM compared to CLL and 
MM (Figure 3 and Table 2). The specificity of this WM signature was further tested 
by LOOCV. Using both KNN and SVM, all the WM were correctly predicted. Of all 
the non-WM cases, only 1 case was not predicted by KNN (did not pass the P value 
ratio) and wrongly predicted by SVM. Forty-eight of these were up-regulated and 
25 down-regulated in WM. Interestingly, the most significantly up-regulated gene in 
WM is IL6. The aforementioned CD1C was also among the top 10 most significantly 
up-regulated genes.
A total of 396 genes had a distinct expression profile in CLL compared to WM 
and MM; 174 of these genes were up-regulated and 222 down-regulated in CLL. 
As expected, up-regulated genes included BCL2 and ZAP70. Among the down-
regulated genes were cell-cycle-related genes (CDC2, CDC20, NEK2), and several 
CDKI (CDKN1C, CDKN1A, CDKN2C).
A total of 1247 genes had a distinct expression pattern in MM compared to CLL 
and WM; 577 of these were up-regulated and 670 down-regulated in MM. Many of 
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the up-regulated genes are involved in signaling pathways known to be important 
in MM such as WNT signaling (DKK1, FRZB,WNT10B, WNT5A, FZD6, WNT6), IL6R, 
IGF1R, MET (HGF receptor) and HGF. Among the down-regulated genes were sev-
eral known to be important in early B cell receptor signaling and differentiation that 
tend to be down-regulated with terminal differentiation to PCs (PAX5, CD19, VAV). 
The top 10 up- and down-regulated genes and other selected genes of interest in 
WM, CLL and MM are appended in table 2, 3 and 4, respectively (for the full gene 
lists, please refer to supplementary material)11.
When these disease specific genes were analyzed for relevant processes and 
pathways using Metacore, interesting differences were obtained. The gene ontol-
ogy (GO) processes most associated with the genes unique to MM were involved 
in signal transduction and intracellular signaling, in particular cell-surface receptor 
linked signaling whereas the most relevant pathways includes AKT, IGF-1R and 
WNT signaling as well as prostacyclin synthesis, angiopoietin signaling, and integrin 
mediated cell adhesion. For CLL, the relevant processes were immune response, 
apoptosis and cell cycle regulation and the most relevant pathways were involved in 
apoptosis regulation (data not shown). Due to the small list of genes unique to WM, 
no significant pathways related to the set of genes were detected. However, the most 
 
Figure 3. Gene-expression signature unique to WM. Seventy-three genes, 48 up-regulated and 25 down-regulated constitute 
a gene-expression signature unique to WM. Here the samples are ordered according to diagnosis and genes according to fold 
difference in expression between WM and CLL and MM. Some interesting genes are highlighted. For a more complete list see 
supplementary material. The scale of the gene-expression data is similar to figure 1a.
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relevant GO process is in activation of MAPK activity. Of note, the MAPK cascade is 
one of signaling pathways activated by IL-6 20.
Table 2. Genes with unique gene-expression profile in WM (The top 10 up- and down-regulated genes plus other genes of 
interest are shown).
 
Probe P-Value Gene Names
Fold Change Rel 
to MM
Fold Change Rel to 
CLL Descriptions
Up-regulated in WM compared to CLL and MM
205207_at 4.31E-10 IL6 4.39 6.41 interleukin 6 (interferon, beta 2)
204081_at 2.49E-08 NRGN 3.23 5.38 neurogranin (protein kinase C substrate, RC3)
201310_s_at 2.51E-07 P311 4.9 6.29 P311 protein
209626_s_at 1.02E-06 OSBPL3 3.63 2.77 oxysterol binding protein-like 3
205987_at 1.06E-05 CD1C 24.4 17.99 CD1C antigen, c polypeptide
210640_s_at 1.80E-05 GPR30 9.75 8.93 G protein-coupled receptor 30
205240_at 2.82E-05 HSU54999 2.28 3.66 LGN protein
211829_s_at 4.80E-05 GPR30 6.08 8.93 G protein-coupled receptor 30
202497_x_at 5.01E-05 SLC2A3 7.55 4.39 solute carrier family 2 (facilitated glucose transporter), member 3
215464_s_at 5.75E-05 TIP-1 4.1 4.85 Tax interaction protein 1
209053_s_at 0.0035779 WHSC1 3.12 2.94 Wolf-Hirschhorn syndrome candidate 1
Down-regulated in WM compared to CLL and MM
222154_s_at 3.70E-08 DKFZP564A2416 6.33 6.64 DKFZP564A2416 protein
219878_s_at 2.57E-07 KLF13 5.99 6.04 Kruppel-like factor 13
221163_s_at 1.66E-06 WBSCR14 3.39 4.58
216869_at 2.01E-06 PDE1C 2.42 3.21 PDE1C3 splice variant; 3',5' cyclic nucleotide phosphodiesterase
218182_s_at 6.47E-06 CLDN1 2.05 3.55 claudin 1
219630_at 6.83E-06 DD96 2.16 3.22 epithelial protein up-regulated in carcinoma, membrane associated 
protein 17
206736_x_at 1.12E-05 CHRNA4 3.09 3.75 cholinergic receptor, nicotinic, alpha polypeptide 4
206994_at 1.26E-04 CST4 3.24 2.97 cystatin S
215967_s_at 1.33E-04 LY9 3.27 2.93 lymphocyte antigen 9
207553_at 1.48E-04 OPRK1 3.88 3.09 opioid receptor, kappa 1
Table 3. Genes with unique expression profile in CLL (The top 10 up- and down-regulated genes plus other genes of interest are 
shown).
 
Probe P-Value Gene Names
Fold Change Rel to 
MM
Fold Change Rel to 
WM Description
Up-regulated in CLL compared to WM and MM
218704_at 1.80E-27 FLJ20315 3.34 3.15 hypothetical protein FLJ20315
221010_s_at 8.59E-21 SIRT5 3.44 2.86 sirtuin silent mating type information regulation 2 homolog 5
203072_at 3.00E-18 MYO1E 7.97 7.77 myosin IE
204155_s_at 6.06E-16 KIAA0999 3.51 2.83 ESTs
204446_s_at 1.74E-15 ALOX5 9.13 8.97 arachidonate 5-lipoxygenase
208858_s_at 3.47E-15 KIAA0747 4.95 4.93 KIAA0747 protein
214366_s_at 7.54E-15 ALOX5 7.66 4.36 arachidonate 5-lipoxygenase
208269_s_at 1.82E-14 ADAM28 38.87 5.47 a disintegrin and metalloproteinase domain 28
205389_s_at 4.34E-14 ANK1 10.23 4.74 ankyrin 1, erythrocytic
209670_at 2.15E-12 TRAC 13.03 7.38 T-cell receptor alpha-chain (VDJC); Human T-cell receptor active alpha-
chain mRNA from JM cell line, complete cds.
203685_at 1.38E-09 BCL2 3.96 3.01 B-cell CLL/lymphoma 2
214032_at 1.46E-04 ZAP70 11.79 6.71 zeta-chain (TCR) associated protein kinase (70 kD)
Down-regulated in CLL compared to WM and MM
222315_at 8.41E-24 ESTs 28.09 40 ESTs
202768_at 2.64E-22 FOSB 82.6 107.76 FBJ murine osteosarcoma viral oncogene homolog B
202708_s_at 2.37E-19 H2BFQ 4.88 3.07 H2B histone family, member Q
201830_s_at 8.07E-16 NET1 19.4 23.7 neuroepithelial cell transforming gene 1
201694_s_at 4.47E-14 EGR1 8.62 6.41 early growth response 1
205780_at 7.42E-14 BIK 9.61 16.8 BCL2-interacting killer (apoptosis-inducing)
202733_at 1.64E-12 P4HA2 3.32 3.1 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-
hydroxylase), alpha polypeptide II
211143_x_at 1.71E-12 NR4A1 3.95 3.19 nuclear receptor subfamily 4, group A, member 1
202095_s_at 2.42E-12 BIRC5 4.78 6.41 baculoviral IAP repeat-containing 5 (survivin)
209911_x_at 1.13E-11 H2BFB 4.88 2.94 H2B histone family, member B
204493_at 1.19E-07 BID 9.26 6.21 BH3 interacting domain death agonist
213182_x_at 3.86E-07 CDKN1C 4.33 6.94 cyclin-dependent kinase inhibitor 1C (p57, Kip2)
200670_at 1.30E-05 XBP1 13.73 7.81 X-box binding protein 1
203362_s_at 2.68E-05 MAD2L1 3.34 3.53 MAD2 mitotic arrest deficient-like 1 (yeast)
206665_s_at 3.01E-05 BCL2L1 8.2 4.67 BCL2-like 1
209642_at 5.75E-05 BUB1 3.05 3.1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast)
202284_s_at 7.99E-05 CDKN1A 15.27 9 cyclin-dependent kinase inhibitor 1A (p21, Cip1)
202870_s_at 2.07E-04 CDC20 4.44 7.58 CDC20 cell division cycle 20 homolog (S. cerevisiae)
210559_s_at 2.37E-04 CDC2 3.36 4.08 Homo sapiens mRNA for CDC2 delta T, complete cds.
211792_s_at 0.001266 CDKN2C 3.25 3.05 cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)
204641_at 0.005091 NEK2 3.51 5.6 NIMA (never in mitosis gene a)-related kinase 2
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discussion
To our knowledge, this is the first gene-expression profiling study in WM and its 
contrast to other B-cell malignancies. In this study, we attempt to define a molecular 
signature of WM in the context of normal cellular counterparts (B-cells and PCs) and 
malignant cells in related B-cell malignancies (CLL and MM).
WM has a homogeneous transcription profile, clusters with CLL and normal B-cells 
on unsupervised clustering and clearly has a similar expression profile to CLL. In 
contrast, the expression profile of WM is very different from MM and normal PCs. 
Previous studies have shown that CLL, regardless of immunoglobulin heavy chain 
(IgH) mutation status, has a homogeneous expression profile 8,21 very similar to 
peripheral blood resting B-cells 11,21. In another study comparing CLL to different 
tonsillar B-cell populations, the expression profile of CLL is most closely related to 
memory B-cells,8 which also constitutes a significant population of the peripheral-
blood B-cell pool 22. The similarity between the expression profile of WM and CLL 
is perhaps not surprising given the known biological and clinical characteristics of 
these diseases. Both are indolent tumors characterized by low proliferation. Unlike 
Table 4. Genes with unique expression profile in MM (The top 10 up- and down-regulated genes plus other genes of interest 
are shown).
 
Probe P-Value Gene Name
Fold Change Rel to 
WM
Fold Change Rel to 
CLL Description
Up-regulated in MM compared to CLL and WM
212253_x_at 3.74E-28 BPAG1 3.52 5.62 bullous pemphigoid antigen 1 (230/240kD)
201064_s_at 4.27E-24 PABPC4 2.36 4.22 poly(A) binding protein, cytoplasmic 4 (inducible form)
209968_s_at 2.62E-23 NCAM1 2.3 4.1 neural cell adhesion molecule 1
204271_s_at 1.23E-20 EDNRB 17.6 12.5 endothelin receptor type B
205309_at 3.40E-17 ASML3B 3.41 4.67 acid sphingomyelinase-like phosphodiesterase
204602_at 5.92E-17 DKK1 9.9 7.41 dickkopf homolog 1 (Xenopus laevis)
202973_x_at 8.46E-17 KIAA0914 5.56 6.53 KIAA0914 gene product
203697_at 2.07E-16 Frizzled-related protein 13.61 17.6 FRZB; frizzled protein homolog
202170_s_at 4.42E-16 AASDHPPT 2.11 2.58 aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase
215059_at 1.27E-15 Homo sapiens mRNA; cDNA 
DKFZp564G112 (from clone 
DKFZp564G112)
6.76 10.76 Homo sapiens mRNA; cDNA DKFZp564G112 (from clone DKFZp564G112)
210755_at 2.15E-12 HGF 4.18 3.36 hepatocyte growth factor (hepapoietin A; scatter factor)
209347_s_at 1.15E-06 MAF 2.43 2.78 v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian)
205071_x_at 2.94E-10 XRCC4 5.26 6.58 X-ray repair complementing defective repair in Chinese hamster cells 4
206213_at 5.20E-06 WNT10B 2.72 4.72 wingless-type MMTV integration site family, member 10B
213693_s_at 1.02E-05 MUC1 2.22 2.61 mucin 1, transmembrane
213425_at 4.20E-05 WNT5A 3.33 4.55 wingless-type MMTV integration site family, member 5A
203510_at 5.69E-05 MET 4.27 4.9 met proto-oncogene (hepatocyte growth factor receptor)
212097_at 7.15E-05 CAV1 17.45 18.7 caveolin 1, caveolae protein, 22kD
205945_at 5.72E-04 IL6R 2.48 3.41 interleukin 6 receptor
203987_at 7.81E-04 FZD6 2.87 4.97 frizzled homolog 6 (Drosophila)
221609_s_at 9.71E-04 WNT6 2.26 2.73 wingless-type MMTV integration site family, member 6
203628_at 0.018357 IGF1R 2.33 2.85 insulin-like growth factor 1 receptor
Down-regulated in MM compared to CLL and WM
209269_s_at 3.99E-38 SYK
30.17 26.91
Spleen tyrosine kinase
34210_at 1.84E-34 CD52 94.71 180.4 CAMPATH-1 (HUMAN);, mRNA sequence.
215537_x_at 3.06E-29 DDAH2 5.04 7.25 dimethylarginine dimethylaminohydrolase 2
204661_at 6.88E-28 CD52 62.91 115.2 CDW52 antigen (CAMPATH-1 antigen)
201721_s_at 2.21E-26 LAPTM5 9.51 16.39 Lysosomal-associated multispanning membrane protein-5
203037_s_at 1.96E-25 KIAA0429 10.66 KIAA0429 gene product
216237_s_at 3.75E-23 MCM5 5.2 8.1 MCM5 minichromosome maintenance deficient 5, cell division cycle 46 (S. 
cerevisiae)
201954_at 5.40E-23 ARPC1B 2.08 3.51 actin related protein 2/3 complex, subunit 1B (41 kD)
41220_at 3.86E-22 MSF 3.8 7.59 MLL septin-like fusion
200934_at 8.18E-22 DEK 21.98 28.82 DEK oncogene (DNA binding)
221969_at 1.51E-15 PAX5 6.58 12.04 ESTs, Weakly similar to S57447 HPBRII-7 protein [H.sapiens]
206398_s_at 8.54E-15 CD19 23.57 45.66 CD19 antigen
205536_at 1.39E-10 VAV2 2.76 4.82 vav 2 oncogene
218806_s_at 1.42E-06 VAV3 2.86 5.21 vav 3 oncogene
202414_at 2.53E-06 ERCC5 2.03 3.01 excision repair cross-complementing rodent repair deficiency, 
complementation group 5 (xeroderma pigmentosum,)
204054_at 2.93E-05 PTEN 2.05 2.64 phosphatase and tensin homolog 
212888_at 3.40E-05 DICER1 2.32 2.88 Homo sapiens clone 23938 mRNA sequence
209193_at 5.19E-05 PIM1 3.18 3.06 pim-1 oncogene
201700_at 2.22E-04 CCND3 3.07 3.78 cyclin D3
205647_at 6.49E-04 RAD52 2.45 4.22 RAD52 homolog (S. cerevisiae)
216299_s_at 0.001976 XRCC3 3.1 3.17 X-ray repair complementing defective repair in Chinese hamster cells 3
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other B-cell malignancies, chromosomal translocations involving the IgH locus are 
relatively uncommon in both CLL and WM 23,24. These IgH translocations are thought 
to occur either during immunoglobulin VDJ recombination in maturing B-cells or 
during Ig somatic hypermutation and isotype switching in mature B cells within the 
germinal center (GC) 25. They are therefore common in B-cell lymphomas which are 
usually derived from GC B-cells 26. This observation is consistent with the notion that 
both CLL and WM are derived from memory B-cells where these mechanisms have 
been inactivated. Despite these similarities, differences such as differential expression 
of immunophenotypic markers and demographics in IgVH mutation status (almost 
all WM are IgV mutated 3,27 compared to 50-70% of CLLs 28,29) suggest that they may 
be derived from different memory B-cell populations 22.
It is possible that the expression profile of WM is closer to normal B-cells and CLL 
than MM and normal PCs due to the additional CD19+ selection (normal B-cells and 
CLL are CD19+ selected) as compared to only CD138+ selection in MM and normal 
PCs. There are several arguments against this; (1) the bulk of CD19+ cells should 
represent the cell of interest (malignant WM and CLL cells and normal B-cells); (2) 
the tissue source for CD19 selection is different (BM for WM and peripheral blood for 
normal B-cells and CLL) and hence the predominant non-malignant B-cell popula-
tion selected should be different (pre-B cells for WM and mature B-cells for CLL); (3) 
WM but not CLL samples are additionally CD138 selected. Furthermore, our strategy 
of using both CD138 and CD19 to select for malignant WM cells has the added 
advantage of allowing the analysis of the entire malignant population. Therefore, the 
respective expression signature should, in general, reflect tumor phenotype rather 
than contaminating cells or other by-products resulting from CD19 selection. The 
similarity between WM and CLL and not MM is further confirmed using indepen-
dently derived CLL and MM signatures.
Detailed analysis of gene-expression for CD markers and genes involve in cell-cycle 
regulation also show similarities between WM and CLL and normal B-cells but not 
MM and normal PCs. In total our analysis suggests that WM is defined by a B-cell-like 
signature and in terms of gene transcription signature is closer to CLL than MM. The 
clustering of the IgM MGUS case together with WM and the similar expression of 
genes with expression profile unique to WM (IL6 and CD1c; data not shown) suggest 
a shared phenotype between IgM MGUS and WM. This is consistent with current 
notion that a subset of IgM MGUS represents the precursor state of WM 30.
Defining genes with unique expression in a disease may provide insight into its 
biology. This would be particularly useful in WM where little is known about its biol-
ogy. Despite the purity of greater than 90% in most samples after immunomagnetic 
bead-positive selection, presence of contaminating normal cells may still contribute 
to the overall gene-expression profile. In our dataset, we noted signatures of con-
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taminating monocyte/macrophages and pre-B-cells, particularly in the samples with 
lower number of target cells (eg, MGUS, normal samples and WM with lower BM 
involvement). To ensure that all the genes with unique expression profiles in each 
of the malignant conditions are relevant to the malignant cells, we subtracted genes 
that constitute the signature of contaminating cell types. Only a small set of genes 
have a unique expression profile in WM. Among the up-regulated genes, IL6 is the 
most significant. It has been demonstrated that IL-6 levels are elevated in WM 31,32 
and that IL-6 is required for plasmacytic differentiation of the clonal B-cells in WM 
33. However, remarkably little is published regarding the potential role of IL-6 in WM 
biology given its prominent role as a growth and survival factor in MM 34,35. Our data 
regarding IL6 expression in WM is validated by 2 abstract presentations that used 
gene-expression approaches. In the first study, GEP identified deregulated elements 
in the IL-6 signaling cascade 36 whereas in the second study utilizing similar analysis 
approach as ours they found that IL6 expression is higher in WM B-cells than normal 
B-cells 37. Its potential relevance to WM biology is highlighted by the fact that the 
GO process most relevant to the WM unique genes in our study is activation of 
MAPK, which is involved in IL-6 signaling 20. Furthermore, as our gene-expression 
analysis is performed on highly purified malignant cells and not total bone marrow 
cells (ie, including stromal cells), the differential expression of IL-6 in WM cells is 
more supportive of an autocrine source for IL-6 in WM compared to MM where the 
source of IL6 is predominantly from the stromal cells. The functional and biological 
importance of IL6 in WM should be investigated as this may represent an important 
therapeutic avenue.
As for CLL and MM, the differentially expressed genes suggest that apoptosis 
regulation and receptor mediated signal transduction are critical processes central 
to CLL and MM biology, respectively. These results are consistent with the known 
biochemical and signaling pathways found in the malignant B cells from MM and 
CLL patients. It is well known that MM growth and survival is mediated through vari-
ous cytokines secreted by stromal cells in the bone marrow milieu upon interaction 
with MM cells 34,35. Similarly, the fundamental role of anti-apoptosis mechanisms is 
well established in CLL 38. More importantly, this comparative analysis shows that 
different pathways are deregulated in these tumors.
In conclusion, our GEP study suggests that WM samples have a homogenous ex-
pression profile very similar to CLL and normal peripheral blood B-cells. A small set 
of genes is distinctly expressed in WM, with IL6 the most significantly up-regulated 
gene. These genes are most significantly associated with MAPK signaling. This in 
turn suggests that IL-6 and its signaling network may be of biological significance 
in WM.
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This thesis deals with the genetics and cytogenetics of Waldenström macroglobu-
linemia (WM). Knowledge of the genetic profile may increase our understanding of 
the disease etiology and pathogenesis. In addition, the identification of cytogenetic 
aberrations or aberrant gene expression can be used as disease specific and/or 
prognostic markers and ultimately also as a focus for the development of targeted 
therapeutics.
In the studies described in this thesis we found that WM displays a distinct genetic 
pattern, which is different from that of multiple myeloma (MM) but more similar to 
that of chronic lymphocytic leukemia (CLL). In this chapter we shall summarize the 
genetic findings in WM and discuss their implications for clinical diagnosis.
igh translocation
According to the WHO classification of tumours, WM and lymphoplasmacytic 
lymphoma (LPL) share the same pathologic designation.1 The translocation t(9;14)
(p13;q32) involving the PAX-5 and IgH genes has been detected in 50% of LPL 
patients and therefore are often assumed also to be present in WM.2,3 The transloca-
tion results in the up-regulation of PAX-5, a gene that encodes a transcription factor, 
B-cell specific activation protein (BSAP).4 BSAP is a protein that is critical for B-cell 
development, but it is not expressed in normal and malignant plasma cells.5,6 The 
original publication had reported the t(9;14) in 4 cases of LPL and none of these 
patients had presented with paraproteinemia. These observations are consistent with 
the potential effect of PAX-5 overexpression to down-regulate IgH transcription.7,8 
Hence, t(9;14)(p13;q32) would not be expected to be present in WM, a form of LPL 
with paraproteinemia.
In the fluorescence in situ hybridization (FISH) studies of chapter 3, t(9;14) could 
not be demonstrated in 31 cases of WM. Thus, unlike MM, translocations involving 
the IgH locus (at 14q32) appear uncommon in WM. Our finding is in agreement with 
other previously reported karyotype studies in patients with WM, where chromo-
some 14 abnormalities were not detected.9 Also, in a FISH study by Chang et al 
IgH translocation were described in only 3 out of 22 WM cases, while no common 
partner chromosome (4p14, 8q24, 11q13 or 16q32) could be detected.10 In a third 
larger FISH study among 69 WM cases IgH translocations were identified in two 
cases only.11 Of note, the infrequent presence of IgH translocations in WM could 
probably be useful in diagnostic dilemmas in particular patients. Avet-Loiseau et al 
showed that the presence of t(11;14) discriminates IgM MM from WM.12
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Finally, a study by Cook et al reassessed the prevalence of t(9;14) in 12 nodal LPLs. 
Contrary to the original report by Offit et al, no t(9;14) was found and all LPL cases 
were negative for IgH translocations.13
Altogether, these studies show that IgH translocations are quite uncommon in LPL/
WM as they are seen in a minority subset of cases. Especially t(9;14) should not be 
considered a LPL/WM specific cytogenetic characteristic, as defined by the WHO 
classification of tumours. These cytogenetic data also suggest that WM differs from 
MM, in which IgH translocations are commonly detected and may represent early 
events in the pathogenesis.
deletion 6q
Based on karyotype studies, deletion of the long arm of chromosome 6 (6q) was 
identified as the most common chromosomal abnormality in WM (chapter 3).9 Us-
ing the more sensitive interphase FISH technique, hemizygous deletions 6q were 
detected in 50% of cases. A recent FISH study by Chang et al used probes located 
at 6q21 and 6q25 and detected the presence of 6q deletions (either 6q21 or 6q25) 
in 13 out of 34 WM cases (38%).14 Our collaborative study with the Spanish group 
from Salamanca involves a total of 102 WM cases. In the latter series, described in 
chapter 5, the same prevalence of deletion 6q21 was found (39%). In this study, due 
to different sensitivities of techniques, the percentages of cases with 6q deletions 
was higher in patients analyzed by cytoplasmic IgM enhanced FISH (54%) than in 
cases studies by conventional FISH (30%). The highest prevalence of 6q deletions 
(55%) was found in our study when we used multiple FISH probes along the whole 
6q arm in 38 WM cases (chapter 4). We also observed that many WM cases displayed 
loss of almost the complete 6q arm. Nevertheless, a minimal region of deletion was 
delineated between 6q23 and 6q24.3 and the FISH probe covering the SRPRH gene 
was deleted most frequently. A pathogenetic role of the latter gene and several 
other candidate tumor suppressor genes such as BLIMP-1 and MYB, have been 
suggested for this area but additional structural and functional studies will be needed 
to elucidate the biological basis of the 6q deletion in WM.
Due to the absence of 6q deletions in IgM MGUS, a precursor stage of particularly 
WM, we speculate that this deletion is a secondary event and maybe associated 
with disease progression. The prognostic significance for 6q deletion in WM was 
investigated in the cohort of 102 WM patients (chapter 5). Cases of WM with a 6q 
deletion displayed features of adverse prognosis (higher levels of β2-microglobulin 
and M-protein, anemia and hypoalbuminemia) and showed a trend to have more 
advanced stages of disease according to the International Staging System (ISS).15 
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Also, the treatment-free survival was negatively influenced by the presence of the 
6q deletion in smoldering WM patients. Survival analysis in our limited series did 
not reveal a negative impact of the presence of a 6q deletion. However the lack of 
an apparent effect of 6q- deletions on survival is not too surprising as this is most 
likely explained by the limited statistical power and the short follow-up time of this 
indolent disease. Contrary to our results, Chang et al had not found evidence for a 
correlation between 6q deletion and clinical or biological parameters. In their study 
of 34 cases, a significant difference in overall survival was neither observed between 
the 6q deletion and non-deletion subgroups. For the time being it remains unclear if 
the 6q deletion can be used as prognostic marker for WM outcome. The 6q deletion 
is the most frequent chromosomal structural aberration in WM. The high prevalence 
of 6q deletion and its unique presentation in WM, compared to nodal LPL16 or IgM 
MGUS, suggest a differential cytogenetic profile associated with this abnormality.
other structural chromosomal aberrations
Abnormalities, like deletions 13q and 17p are commonly found in MM and are gener-
ally recognized as adverse prognostic abnormalities. We showed that compared to 
MM, deletions 13q and 17p are less common in WM at time of diagnosis, but they 
may be observed in 15% at the time of disease progression (chapter 2). Chang et al 
found deletions of 13q or 17p in 9% of 22 WM.10 Nevertheless, due to low sample 
number, this study was unable to address the question of the prognostic significance 
of these deletions.
Sporadic WM case studies have reported the translocation t(11;18)(q21;q21).17 This 
translocation is associated with extranodal marginal zone lymphoma. In our series of 
24 WM cases this translocation was not detected by FISH.
Aneuploidy is common in MM and based on the type of numerical chromosomal 
abnormalities, four categories can be identified: hypodiploid, pseudodiploid, hyper-
diploid and near-tetraploid. IgH translocations and deletion 13 are closely related 
with the the non-hyperdiploid MM categories. Based on these cytogenetic data two 
prognostically different groups can be detected: non-hyperdiploid MM with IgH 
translocation (unfavorable) and hyperdiploid MM without IgH translocations (favor-
able). It is postulated that these two groups represent different pathogenic pathways 
of MM.18,19 To assess the ploidy status in WM we performed multicolor (M)-FISH in 
5 cases and interphase FISH using centromere enumeration probes (CEPs) in 15 
cases (chapter 3). Although some patients featured abnormalities in the karyotype 
consistent with aneuploidy, interphase FISH showed that this is the exception in 
WM. The absence of aneuploidy (hyperdipliody) together with the infrequent pres-
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ence of IgH translocations, suggest that WM does not share either of the proposed 
pathogenic pathways of MM.
comParative gene exPression Profiling
In the gene expression profiling (GEP) study of WM in chapter 6 we compared 
CD19+ and CD138+ WM bone marrow cells with other B-cell malignancies (CLL and 
MM) and B-cells and plasma cells as their normal cellular counterparts. The 23 WM 
cases display a homogeneous single expression pattern. Importantly, 6q deleted and 
non-deleted WM cases do not form distinct clusters, when we use all genes on the 
Affymetrix U133A chip. This suggests that loss of genes located at 6q does not lead 
to profound transcriptional changes. Several reasons can be given, why 6q deleted 
and non-deleted do not form distinct clusters in our GEP study. First, this could be 
explained by the small samples size of WM cases. Second, it is easier to detect a gene 
dosage effect, when there is gain of chromosome because the dynamic range for in-
crease in gene expression is much higher compared to deletion or under-expression. 
Third, the microarray platform we used only represented a part of the human genes. 
Consequently, it is possible that genes critical in WM pathogenesis are missed in this 
GEP study. Finally, we compared 6q deleted and non-deleted WM, using all genes 
on the U133A chip. A supervised analysis, using only the 6q genes, could reveal 
specific expression differences between the 6q deleted and non-deleted WM.
The WM expression pattern resembles that of CLL and normal B-cells. The gene 
expression pattern of WM is different from MM and normal plasma cells.
Only a small set of genes was found to be specific for WM. Among the upregulated 
genes, IL6 was the most significant. IL-6 levels are known to be high in WM and 
this cytokine is required for plasmacytic differentiation in WM B-cells.20,21 Moreover, 
IL-6 is among the most important proliferation and survival factors in MM.22,23 The 
potential pathogenic role for IL-6 in WM was also suggested by Guttierrez et al.24 In 
their gene expression profiling study they compared clonal WM B-cells with clonal 
WM plasma cells. They observed a different gene expression pattern between the 
WM B-cell population and the WM plasma cell population. IL-6 was elevated in the 
B-cell subset of WM clonal cells. This cytokine is currently considered as possible 
therapeutic target and could explain the elevated levels of C-reactive protein in WM 
patients.
In summary, we conclude that WM shows a gene expression profile more similar 
to that of CLL than that of MM and that further study is warranted to elucidate the 
potential pathogenic role of IL-6 production in WM clonal cells.
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future PersPectives
Together with the sequencing of the entire human genome, microarray techniques 
appear useful for understanding tumorigenesis at distinct cellular levels, such as 
protein, RNA, micro-RNA, single nucleotide polymorphisms (SNPs), DNA and DNA 
methylation.
A combined strategy using different microarray platforms in the same tumor 
samples could screen for recurrent or sporadic aberrations and at the same time 
could give more insights of its consequences. For example, recurrent small biallelic 
deletions could identify regions that potentially harbor tumor suppressor genes. If 
those identified genes belong to a known common pathway, a working hypothesis 
can be formulated about its role in tumorigenesis. Subsequent analysis of GEP data 
could reveal dysregulated expression of those target genes involved in this pathway. 
Additional mutation analyses can establish an overall rate of altered target genes. 
To validate the role of possible tumor suppressor genes, reintroduction of the wild-
type gene into a tumor cell line model can be used to test the hypothesis. It is this 
combined strategy that was used in a recent MM paper that identified an array 
of mutations that result in activation of the noncanonical NF-κB pathway.25 These 
observations provided valuable insight into the significant contribution of the non-
canonical NF-κB pathway in the pathogenesis of MM, which was also highlighted by 
the clinical success of bortezomib, a postulated NF-κB inhibitor.
A pathway-centric approach was also suggested by Wood et al. as a new paradigm 
of cancer research.26 Genome-wide sequencing of gene transcripts in breast and 
colorectal cancers identified a few gene mutations at high frequency and a much 
larger number of genes mutated at low frequency. It appears that those sporadic 
mutated genes exert tumorigenesis through known cellular signaling pathways. The 
authors stated that through array-based techniques future cancer research will easily 
identify genetic alterations, but will be challenged to comprehend its precise role of 
these alterations in cellular pathways and tumorigenesis.
Using the same approach for WM, will benefit the understanding of molecular 
pathways involved in the pathogenesis of WM. These array-based techniques may 
also evolve into practical clinical tools and therefore guide (WM) patient manage-
ment in the near future.
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Summary
Waldenström macroglobulinemia (WM) is a rare incurable disease, characterized 
by an expansion in the bone marrow of a subpopulation of white blood cells, the 
B-lymphocytes. These cells produce an abnormal excessive amount of antibody 
protein, immunoglobulin M (IgM).
High blood concentration of this monoclonal gammopathy or IgM M-protein, 
eventually leads to thickening of the blood, resulting in hampered blood flow caus-
ing the hyperviscosity syndrome. Important symptoms of this syndrome are fatigue, 
visual problems, a tendency to bleed easily, headache, dizziness, deafness, kidney 
failure and heart failure. Also, bone marrow expansion of B-cells compromises nor-
mal blood cell production, causing anemia, shortage of normal white blood cells, 
resulting in a higher infection risk, and lowered platelet counts, necessary for blood 
clotting.
In some patients, the IgM protein interacts with nerve tissue, resulting in tingling 
of hands and feet, loss of sensation and muscle weakness.
Because of the relative indolent course of the disease WM, treatment is usually not 
immediately required at the time of diagnosis. WM patients can be without treatment 
for many years. Nevertheless, some patients have progressive disease and need in-
stant chemotherapy. The cause of this heterogeneity in clinical behavior is unclear.
More understanding of the cause of WM could give more insight. Many acquired 
chromosomal abnormalities have been found in other malignant blood diseases and 
sometimes gave insight into biological processes that contribute to the development 
of that disease. Knowledge of these processes can provide potential targets for novel 
drug development.
In addition, in some cases certain chromosomal abnormalities can predict the 
clinical course of the disease. Specific chromosomal abnormalities are characteristic 
for a particular disease and therefore can be helpful in making the correct diagnosis 
and subsequent treatment choices.
This thesis contains studies that give more insight into the presence of chromosomal 
abnormalities in WM compared to related disorders such as monoclonal gammopa-
thy of undetermined significance (MGUS) and malignant blood diseases like chronic 
lymphocytic leukemia and multiple myeloma.
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Besides the search for chromosomal abnormalities in WM, we used the microarray 
technique, to look more detailed at gene expression level patterns in WM compared 
to the above mentioned related diseases.
Chapter 1 is a general introduction, which describes the clinical characteristics of 
Waldenström macroglobulinemia and the necessity of more knowledge of chromo-
somal abnormalities.
Chapter 2 contains the results of cytogenetics analysis on bone marrow tissue 
of WM patients by using the fluorescent in situ hybridization (FISH) technique. We 
looked specific for the presence of loss of chromosome 13 (13q) and the short arm 
of chromosome 17 (17p). These abnormalities are known to be associated with an 
aggressive course of multiple myeloma. Our results showed that both chromosomal 
abnormalities are uncommon in WM. Nevertheless, when present in WM, then they 
are associated with a worse prognosis in WM.
In chapter 3 we present FISH data of 31 WM patients indicating that translocations 
between chromosome 14 and other chromosomes, specifically chromosome 9, are 
rare. Also numerical abnormalities of complete chromosomes were uncommon. In 
contrast, both translocations involving chromosome 14 and numerical chromosome 
changes are frequently found in multiple myeloma. Our findings in WM suggest that 
this disease might differ from multiple myeloma on the genetic level.
Finally, in this chapter we present data of the most frequently found chromosomal 
abnormality in WM; the deletion of the long arm of chromosome 6 (6q). Initially, this 
6q abnormality was found in 50% in our 24 WM patients.
Chapter 4 focuses on the 6q deletion in WM and a pre-malignant state that often 
progresses to WM, IgM MGUS. No 6q deletion was found in bone marrow tissue 
of 12 IgM MGUS cases. This could mean that this abnormality is acquired later in 
the development of WM. This deletion also seems to be limited to a specific region 
of chromosome 6, although most of the time the WM patient has lost one whole 
6q arm. By using FISH we screened the whole 6q arm for deletions. The minimal 
region of deletion is between chromosome band 6q23 and 6q24.3. Knowing the 
minimal deleted region could be helpful identifying important genes within this 
deleted region. Consequently, deletion of these genes can influence their function, 
potentially contributing to the development of WM.
Combining FISH data of WM patients from Spain with our cases, we were able to 
determine the presence prevalence of 6q deletion in a large WM group. In chapter 
5 we show that the frequency is at least 34% using the FISH technique in 102 WM 
cases. Although not statistically significant, there seems to be a tendency towards a 
worse prognosis when a patient has the 6q deletion. Confirmation is needed study-
ing larger groups of WM patients, with a longer follow-up time.
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In chapter 6 we compare mircoarray data of patient material of chronic lympho-
cytic leukemia, multiple myeloma and WM. The microarray technique generates data 
on the the expression level of thousands of genes simultaneously, making it possible 
to assemble specific gene expression profiles. Irrespective of the presence of the 6q 
deletion, our study shows that the gene expression profile of WM is more similar 
to chronic lymphocytic leukemia than to multiple myeloma. Only a small amount 
of the investigated genes distinguishes WM from chronic lymphocytic leukemia and 
multiple myeloma. One of the genes that was more up-regulated in WM compared to 
the other diseases, was the gene that codes for interleukin 6 (IL-6). Previous studies 
have demonstrated that IL-6 is important for B-cell development in WM. Also, IL-6 
is an important factor for growth of multiple myeloma tumor cells. More study is 
needed to know more about the role of IL-6 in the biology of WM clonal B-cells.
Chapter 7 contains a general discussion about our findings in WM compared to 
data of other research groups. We expect that new (cyto)genetic techniques will 
give more insight into the contribution of specific genetic abnormalities to important 
biological pathways in tumor cells in general and in WM B-cells in particular.

Samenvatting
Waldenström macroglobulinemia (WM) is een zeldzame ongeneeslijke kwaadaardige 
ziekte, die gekenmerkt wordt door een ongebreidelde deling in het beenmerg van 
een subpopulatie van witte bloedcellen, de B-lymfocyten. Deze cellen maken een 
abnormale hoeveelheid afweereiwit, immuunglobuline M (IgM).
Deze zogenaamde monoklonale gammopathie of M-proteïne van het type IgM 
leidt uiteindelijk bij hoge bloedconcentraties tot stroperigheid van het bloed en 
doorstroombelemmering, resulterende in het hyperviscositeit syndroom. De be-
langrijkste klachten van dit syndroom zijn vermoeidheid, stoornissen van het zien, 
verhoogde bloedingsneiging, hoofdpijn, duizeligheid, doofheid, verslechterende 
nierfunctie en hartproblemen. Tevens zorgt de woekering van de B-lymfocyten in 
het beenmerg voor verdringing van de aanmaak van andere gezonde bloedcellen, 
leidend tot bloedarmoede, verminderde hoeveelheid afweercellen, resulterend in een 
verhoogde kans op infecties, en verlaagde bloedplaatjes, nodig voor de stolling.
Tenslotte tast in sommige gevallen het abnormale eiwit IgM de zenuwen aan, zich 
uitend in tintelingen aan handen en voeten, gevoelsstoornissen en krachtsverlies.
Door het relatief milde beloop van de ziekte is vaak bij het stellen van de diagnose 
WM behandeling niet meteen noodzakelijk. Bij afwezigheid van klachten kan soms 
jaren gewacht worden met behandeling. Echter, er zijn ook patienten waarbij de 
ziekte sneller verloopt, waardoor behandeling middels chemotherapie noodzakelijk 
wordt. Wat de onderliggende oorzaak van dit verschil in ziektebeloop is onduide-
lijk.
Meer begrip van de oorzaak van WM zou meer inzicht kunnen geven. Verworven 
afwijkingen van chromosomen, dragers van DNA, zijn in andere kwaadaardige 
bloedziekten gevonden en blijken soms duidelijkheid te geven over processen die 
bijdragen aan het ontstaan van de ziekte. Kennis over deze processen biedt aangrij-
pingspunten voor de ontwikkeling van nieuwe werkzame geneesmiddelen. Ook is 
bekend dat chromosoom afwijkingen een voorspellende waarde kunnen hebben 
voor het beloop van de ziekte. Soms zijn kenmerkende chromosoom afwijkingen 
gerelateerd aan een specifieke bloedziekte, zodat onderzoek naar deze afwijking 
behulpzaam kan zijn bij het stellen van de diagnose en het maken van een passende 
behandelkeuzes.
112 Chapter 8
In dit proefschrift worden studies beschreven die meer inzicht geven over de aan-
wezigheid van chromosomale afwijkingen in WM in vergelijking tot de gerelateerde 
aandoening IgM monoclonale gammopathie “of undetermined significance” (MGUS), 
en de kwaadaardige bloedziekten, chronische lymfatische leukemie en multipel my-
eloom. Naast cytogenetisch onderzoek naar chromosoom afwijkingen is met behulp 
van een moleculair biologische techniek, microarray, meer gedetaileerd gekeken 
naar kenmerkende verschillen tussen bovengenoemde gerelateerde ziekten.
Hoofdstuk 1 is een algemene introductie waarin de kenmerken van Waldenström 
macroglobulinemie worden beschreven en de noodzaak voor meer kennis over 
chromosomale afwijkingen.
Hoofdstuk 2 beschrijft de resultaten van cytogenetisch onderzoek op beenmerg 
materiaal van WM patienten met behulp van de techniek fluorescence in situ hybri-
dization (FISH). Er is specifiek gekeken naar verlies van een deel van chromosoom 
13 (13q) en verlies van de korte arm van chromosoom 17 (17p). Het is bekend dat 
deze afwijkingen ook in multipel myeloom voorkomen en geassocieerd zijn met een 
aggressiever ziektebeloop. In WM bleek deze afwijkingen zelden voor te komen. 
Wel bleken ze geassocieerd te zijn met slechter prognose van WM.
In hoofdstuk 3 wordt aangetoond dat met behulp van FISH technieken trans-
locaties tussen chromosoom 14 en andere chromosomen zeldzaam zijn in WM. In 
het bijzonder translocatie tussen chromosoom 9 en 14, welke geassocieerd zou zijn 
met WM, werd in onze studie van 31 patienten niet gevonden. Ook numerieke 
afwijkingen van hele chromosomen waren zeldzaam. Zowel translocaties waarbij 
chromosoom 14 betrokken is, als numerieke chromosomale afwijkingen zijn veel 
voorkomende afwijkingen in multipel myeloom. Onze bevindingen in WM wijzen 
erop dat deze ziekte ook op genetisch niveau verschilt van multipel myeloom.
Tenslotte wordt in dit hoofdstuk de bevinding van de meest voorkomende 
chromosomale afwijking in WM gepresenteerd; de deletie van de lange arm van 
chromosoom 6 (6q). In deze studie wordt deletie 6q in 50% van de 24 WM patienten 
gevonden.
Hoofdstuk 4 focust zich op de 6q chromosoom afwijking in WM en de pre-
maligne aandoening IgM MGUS, die zich vaak uiteindelijk ontwikkeld in WM. In 12 
IgM MGUS patienten kon in het beenmerg geen 6q deletie worden aangetoond. Dit 
kan betekenen dat deze afwijking pas later in de ontwikkeling van WM plaatsvindt. 
Ook lijkt de deletie inWM zich te beperken tot een bepaald gebied op de 6q arm, 
alhoewel meestal de gehele 6q ontbreekt. Met behulp van FISH werd op verschil-
lende lokaties op chromosoom 6 gescreend voor deleties. De minimale grote van 
de deletie lijkt zich te concentreren tussen chromosoom band 6q23 en 6q24.3. De 
kennis van de minimale grootte van de deletie kan behulpzaam zijn bij het vinden 
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van eventuele belangrijke genen gelegen binnen deze deletie, die door deze deletie 
minder functioneel worden en daardoor een bijdrage aan de ontwikkeling van WM 
kunnen leveren.
Samenvoeging van een WM patientengroep uit Spanje met onze patienten, biedt 
de mogelijk te komen tot een beter inzicht in het voorkomen van de deletie 6q. In 
hoofdstuk 5 wordt de analyse van deze groep van 102 WM patienten beschreven, 
waaruit blijkt dat het percentage van 6q deletie minimaal 34% is met behulp van 
de FISH techniek. Alhoewel niet statistisch significant, lijkt de aanwezigheid van de 
6q deletie in WM patienten, geassocieerd te zijn met een slechtere prognose. Het 
zal noodzakelijk zijn een grotere groep patienten langdurig te analyseren om aan 
te tonen of de 6q deletie in WM daadwerkelijk betekenis heeft voor het beloop van 
de ziekte.
Hoofdstuk 6 beschrijft de resultaten van een vergelijkend onderzoek tussen pa-
tienten materiaal van chronische lymfatische leukemie, multipel myeloom en WM, 
waarbij gebruik wordt gemaakt van microarrays, waarmee simultaan het expressieni-
veau van duizenden genen kan worden bepaald. Het totale expressieprofiel van WM 
in onze studie vertoont meer overeenkomsten met chronische lymfatische leukemie 
dan met multipel myeloom. Dit resultaat is onafhankelijk van de aan of afwezigheid 
van de deletie 6q. Van de onderzochte genen, is slechts een klein aantal genen dat 
WM onderscheidt van chronische lymfatische leukemie en multipel myeloom. Van 
deze genen, was in WM het expressieniveau van het gen voor interleukine 6 (IL-6) 
verhoogd in vergelijking tot de andere ziekten. Eerdere studies toonden aan dat het 
boodchappereiwit IL-6 een belangrijke rol speelt in de uitrijping van de B-cellen in 
WM. Ook in multipel myeloom is IL-6 een belangrijke factor voor groei en overle-
ving van de tumorcel. Verdere studies moeten uitwijzen welke rol IL-6 speelt in de 
biologie van klonale B-cellen in WM.
Tenslotte, betreft hoofdstuk 7 een algemene discussie, waarin onze bevindingen 
worden vergeleken met resultaten van andere studies in WM. Ook wordt een toe-
komst perspectief geschetst waarbij met nieuwe (cyto)genetische technieken, meer 
inzicht zal worden verkregen in de cumulatieve bijdrage van specifieke genetische 
afwijkingen aan belangrijke biologische processen in tumorcellen in het algemeen 
en mogelijk WM B-cellen in het bijzonder.
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